<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1902200013
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DUPIXENT 200 mg Solution for Injection in Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DUPILUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4637.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANOFI WINTHROP INDUSTRIE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANOFI WINTHROP INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANOFI AVENTIS GROUPE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Dupixent is</strong></p><p>Dupixent contains the active substance dupilumab.</p><p>&nbsp;</p><p>Dupilumab is a monoclonal antibody (a type of specialised protein) that blocks the action of proteins called IL-4 and IL-13. Both play a major role in causing the signs and symptoms of asthma.</p><p>&nbsp;</p><p><strong>What Dupixent is used for</strong></p><p>Dupixent is used to treat adults and adolescents 12 years and older with moderate-to-severe atopic dermatitis, also known as atopic eczema. Dupixent is also used to treat children 6 to 11 years old with severe atopic dermatitis. Dupixent may be used with eczema medicines that you apply to the skin or it may be used on its own.</p><p>&nbsp;</p><p>Dupixent is used with other asthma medicines for the maintenance treatment of severe asthma in adults and adolescents (12 years of age and older) whose asthma is not controlled with their current asthma medicines.</p><p>&nbsp;</p><p><strong>How Dupixent works</strong></p><p>Using Dupixent for atopic dermatitis (atopic eczema) can improve the condition of your skin and reduce itching. Dupixent has also been shown to improve symptoms of pain, anxiety, and depression associated with atopic dermatitis. In addition, Dupixent helps improve your sleep disturbance and overall quality of life.</p><p>&nbsp;</p><p>Dupixent helps prevent severe asthma attacks (exacerbations) and can improve your breathing. Dupixent may also help reduce the amount of another group of medicines you need to control your asthma, called oral corticosteroids, while preventing severe asthma attacks and improving your breathing.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Dupixent</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB style='mso-no-proof:yes'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_0f73c943-c863-47f5-904d-df5cd0c56c99
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to dupilumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you think you may be allergic, or you are not sure, ask your doctor, pharmacist or nurse for advice before using Dupixent.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB style='mso-no-proof:yes'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_3696f406-ad81-4b24-9ef6-f75630b33dc8
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Talk to your doctor, pharmacist or nurse before using Dupixent:</p><p>&nbsp;</p><p>Dupixent <strong>is not a rescue medicine</strong> and should not be used to treat a sudden asthma attack.</p><p>&nbsp;</p><p><u>Allergic reactions</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rarely, Dupixent can cause serious side effects, including allergic (hypersensitivity) reactions and anaphylactic reaction and angioedema. These reactions can occur from minutes until seven days after Dupixent administration. You must look out for signs of these conditions (i.e. breathing problems, swelling of the face, lips, mouth, throat or tongue, fainting, dizziness, feeling lightheaded (low blood pressure), fever, general ill feeling, swollen lymph nodes, hives, itching, joint pain, skin rash) while you are taking Dupixent. Such signs are listed under &ldquo;Serious side effects&rdquo; in section&nbsp;4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop using Dupixent and tell your doctor or get medical help immediately if you notice any signs of an allergic reaction.</p><p>&nbsp;</p><p><u>Eosinophilic conditions</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rarely patients taking an asthma medicine may develop inflammation of blood vessels or lungs due to an increase of certain white blood cells (eosinophilia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is not known whether this is caused by Dupixent. This usually, but not always, happens in people who also take a steroid medicine which is being stopped or for which the dose is being lowered.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor immediately if you develop a combination of symptoms such as a flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash.</p><p>&nbsp;</p><p><u>Parasitic (intestinal parasites) infection</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dupixent may weaken your resistance to infections caused by parasites. If you already have a parasitic infection it should be treated before you start treatment with Dupixent.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check with your doctor if you have diarrhoea, gas, upset stomach, greasy stools, and dehydration which could be a sign of a parasitic infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you live in a region where these infections are common or if you are travelling to such a region check with your doctor.</p><p>&nbsp;</p><p><u>Asthma</u></p><p>If you have asthma and are taking asthma medicines, do not change or stop your asthma medicine without talking to your doctor. Talk to your doctor before you stop Dupixent or if your asthma remains uncontrolled or worsens during treatment with this medicine.</p><p>&nbsp;</p><p><u>Eye problems</u></p><p>Talk to your doctor if you have any new or worsening eye problems, including eye pain or changes in vision.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The safety and benefits of Dupixent are not yet known in children with atopic dermatitis below the age of 6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The safety and benefits of Dupixent are not yet known in children with asthma below the age of 12.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Dupixent</strong></p><p>Tell your doctor or pharmacist</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are using, have recently used or might use any other medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had or are due to have a vaccination.</p><p>&nbsp;</p><p><strong>Other medicines for asthma</strong></p><p>Do not stop or reduce your asthma medicines, unless instructed by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These medicines (especially ones called corticosteroids) must be stopped gradually.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This must be done under the direct supervision of your doctor and dependent on your response to Dupixent.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ae6420b4-f0d5-4565-aff8-999a846e9c99 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. The effects of this medicine in pregnant women are not known; therefore it is preferable to avoid the use of Dupixent in pregnancy unless your doctor advises to use it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine. You and your doctor should decide if you will breast-feed or use Dupixent. You should not do both.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB style='mso-no-proof:yes'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_aa983f12-a5c6-41b1-8e50-b7de3a6c52a6
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Dupixent is unlikely to influence your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Dupixent contains sodium </strong></p><p>This medicine contains less than 1 mmol sodium (23&nbsp;mg) per 200&nbsp;mg dose, i.e., it is essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How Dupixent is given</strong></p><p>Dupixent is given by injection under the skin (subcutaneous injection).</p><p>&nbsp;</p><p><strong>How much Dupixent you will receive</strong></p><p>Your doctor will decide which dose of Dupixent is right for you.</p><p>&nbsp;</p><p><u>Recommended </u><u>dose in adolescents with atopic dermatitis</u></p><p>The recommended dose of Dupixent for adolescents (12 to 17 years of age) with atopic dermatitis is based on body weight:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body Weight of Patient</strong></p></td><td style="vertical-align:top"><p><strong>Initial</strong><strong> </strong><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Subsequent</strong><strong> Doses (every other week)</strong></p></td></tr><tr><td style="vertical-align:top"><p>less than 60 kg</p></td><td style="vertical-align:top"><p>400 mg (two 200 mg injections)</p></td><td style="vertical-align:top"><p>200 mg</p></td></tr><tr><td style="vertical-align:top"><p>60 kg or more</p></td><td style="vertical-align:top"><p>600 mg (two 300 mg injections)</p></td><td style="vertical-align:top"><p>300 mg</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Recommended </u><u>dose in children with atopic dermatitis</u></p><p>The recommended dose of Dupixent for children (6 to 11 years of age) with atopic dermatitis is based on body weight:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p><strong>Body Weight of Patient</strong></p></td><td style="vertical-align:top"><p><strong>Initial</strong><strong> </strong><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Subsequent</strong><strong> Doses</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15 kg to</p><p>less than 60 kg</p></td><td style="vertical-align:top"><p>300 mg (one 300 mg injection) on Day 1, followed by 300 mg on Day 15</p></td><td style="vertical-align:top"><p>300 mg <strong>every 4 weeks</strong>*,</p><p>starting 4 weeks after Day 15 dose</p></td></tr><tr><td style="vertical-align:top"><p>60 kg or more</p></td><td style="vertical-align:top"><p>600 mg (two 300 mg injections)</p></td><td style="vertical-align:top"><p>300 mg <strong>every other week</strong></p></td></tr></tbody></table><p>* The dose may be increased to 200 mg every other week based on the doctor&rsquo;s opinion.</p><p>&nbsp;</p><p><u>Recommended dose in adult and adolescent patients with asthma (12 years of age and older)</u></p><p>For most patients with severe asthma, the recommended dose of Dupixent is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An initial dose of 400&nbsp;mg (two 200&nbsp;mg injections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Followed by 200&nbsp;mg given every other week administered as subcutaneous injection.</p><p>&nbsp;</p><p>For patients with severe asthma and who are on oral corticosteroids or for patients with severe asthma and co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid severe chronic rhinosinusitis with nasal polyposis, the recommended dose of Dupixent is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An initial dose of 600&nbsp;mg (two 300&nbsp;mg injections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Followed by 300&nbsp;mg given every other week administered as subcutaneous injection.</p><p>&nbsp;</p><p><strong>Injecting Dupixent</strong></p><p>Dupixent is given by injection under your skin (subcutaneous injection). You and your doctor or nurse should decide if you should inject Dupixent yourself.</p><p>&nbsp;</p><p>Before injecting Dupixent yourself you must have been properly trained by your doctor or nurse. Your Dupixent injection may also be given by a caregiver after proper training by a doctor or nurse.</p><p>&nbsp;</p><p>Each pre-filled syringe contains one dose of Dupixent (200&nbsp;mg). Do not shake the pre-filled syringe.</p><p>&nbsp;</p><p>Read the &ldquo;Instructions for Use&rdquo; for the pre-filled syringe carefully before using Dupixent.</p><p><strong>&nbsp;</strong></p><p><strong>If you use more Dupixent than you should</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6f5ca313-3dce-472d-905a-35115b5002c5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you use more Dupixent than you should or the dose has been given too early, talk to your doctor, pharmacist or nurse.<!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_58d1e237-8543-4486-a37a-13a12252e522
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>If you forget to use Dupixent</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_af43ae7a-8728-4cc8-b899-782190df0ed3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you have forgotten to inject a dose of Dupixent, talk to your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>If you stop using Dupixent</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a5b359b1-a700-49a5-be7d-2d06c0fac0f6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Do not stop using Dupixent without speaking to your doctor first.<!--[if supportFields]><span
lang=EN-GB style='mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_9b883138-60fe-444a-9e44-ad0fd3fcb47e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Dupixent can cause serious side effects, including very rare allergic (hypersensitivity) reactions, including anaphylactic reaction; the signs of allergic reaction or anaphylactic reaction may include:</p><p>&middot;&nbsp;&nbsp;&nbsp; breathing problems</p><p>&middot;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth, throat or tongue (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp; fainting, dizziness, feeling lightheaded (low blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp; general ill feeling</p><p>&middot;&nbsp;&nbsp;&nbsp; swollen lymph nodes</p><p>&middot;&nbsp;&nbsp;&nbsp; hives</p><p>&middot;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp; skin rash</p><p>&nbsp;</p><p>If you develop an allergic reaction, stop using Dupixent and talk to your doctor right away.</p><p>&nbsp;</p><p><u>Other side effects</u></p><p><strong>Very Common</strong> (may affect more than 1 in 10 people) atopic dermatitis and asthma:</p><p>&middot;&nbsp;&nbsp;&nbsp; injection site reactions (i.e. redness, swelling, and itching)</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people) atopic dermatitis only:</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp; eye dryness, redness and itching</p><p>&middot;&nbsp;&nbsp;&nbsp; eyelid itching, redness and swelling</p><p>&middot;&nbsp;&nbsp;&nbsp; eye infection</p><p>&middot;&nbsp;&nbsp;&nbsp; cold sores (on lips and skin)</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eye surface, sometimes with blurred vision (keratitis, ulcerative keratitis)</p><p>&nbsp;</p><p><strong>Not known</strong></p><p>The following side effects have been reported since the marketing of Dupixent, but how often they occur is not known:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain (arthralgia)</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o SFDA call center : 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sanofi- Pharmacovigilance:<strong> </strong>KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). If necessary, pre-filled syringes may be kept at room temperature up to 25&deg;C for a maximum of 14&nbsp;days. Do not store above 25&deg;C. If you need to permanently remove the carton from the refrigerator, write down the date of removal in the space provided on the outer carton, and use Dupixent within 14 days.</p><p>&nbsp;</p><p>Store in the original carton to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice that the medicine is cloudy, discoloured, or has particles in it.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your doctor, pharmacist or nurse how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Dupixent contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is dupilumab.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each pre-filled syringe contains 200&nbsp;mg of dupilumab in 1.14 ml solution for injection (injection).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are arginine hydrochloride, histidine, polysorbate 80 (E433), sodium acetate, glacial acetic acid (E260), sucrose, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dupixent is a clear to slightly opalescent, colourless to pale yellow solution supplied in a glass pre-filled syringe.

Dupixent is available as 200 mg pre-filled syringes in a pack containing 1 or 2 pre-filled syringes or in a pack containing 3 (3 packs of 1) or 6 (3 packs of 2) pre-filled syringes. 

Not all pack sizes may be marketed. 
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>sanofi-aventis groupe</p><p>54, rue La Bo&eacute;tie</p><p>75008 Paris</p><p>France</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>SANOFI WINTHROP INDUSTRIE<br />1051 Boulevard Industriel,</p><p>76580 LE TRAIT,</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو دوبيكسنت </strong></p><p dir="RTL">يحتوي دوبيكسنت على المادة الفاعلة دوبيلوماب.</p><p dir="RTL">دوبيلوماب هو جسم مضاد أحاديّ المنشأ (نوع من البروتين المتخصص) يحصر عمل بروتينين يُسميّان IL-4 &nbsp;و IL-13 ويلعبان دورًا رئيسيًا في التسبب بإشارات وعوارض الربو.&nbsp;&nbsp;</p><p dir="RTL"><strong>ما هي دواعي استعمال دوبيكسنت</strong></p><p dir="RTL">يُستعمل دوبيكسنت لعلاج البالغين والمراهقين في عمر 12 سنة وما فوق المصابين بالتهاب الجلد التأتبي المعتدل إلى الحاد، المعروف أيضًا بالأكزيما التأتبيّة. يمكن استعمال دوبيكسنت كذلك لدى الأطفال التي تتراوح أعمارهم بين 6 و11 سنة لعلاج التهاب الجلد التأتبي الحاد. يمكن استعمال دوبيكسنت مع أدوية الأكزيما التي تضعها على الجلد أو يمكن استعماله لوحده.</p><p dir="RTL">يُستعمل دوبيكسنت مع أدوية ربو أخرى لعلاج الصيانة للربو الحاد لدى البالغين والمراهقين (12 سنة وما فوق) الذين لا يكون الربو لديهم متحكّمًا به بأدوية الربو الحاليّة التي يأخذونها.</p><p dir="RTL"><strong>كيف يعمل</strong> <strong>دوبيكسنت</strong></p><p dir="RTL">إنّ استعمال دوبيكسنت لالتهاب الجلد التأتبي (الأكزيما التأتبيّة) يمكن أن يحسّن حالة جلدك ويخفّف من الحكّة. وقد ثَبت أيضًا أنّ دوبيكسنت يحسّن عوارض الألم والقلق والاكتئاب المرتبطة بالتهاب الجلد التأتبي. بالإضافة إلى ذلك، يساعد دوبيكسنت على تحسين اضطرابات النوم والنوعيّة الإجماليّة للحياة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يساعد دوبيكسنت على منع نوبات الربو الحادة (تفاقم الربو) ويمكنه أن يحسّن التنفّس لديك. يمكن أن يساعد دوبيكسنت أيضًا على الحدّ من كميّة مجموعة أخرى من الأدوية تحتاج إليها للتحكّم بالربو الذي تعاني منه وتُسمّى الستيرويدات القشرية عن طريق الفم، مانعًا نوبات الربو الحاد ومحسّنًا التنفّس لديك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل دوبيكسنت</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية ضدّ دوبيلوماب أو ضدّ أيّ من المركّبات الأخرى في هذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعتقد أنّك قد تكون تعاني من حساسيّة أو إذا لم تكن متأكّدًا، استشر الطبيب أو الصيدلي أو الممرّضة قبل استعمال دوبيكسنت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدّث إلى الطبيب أو الصيدلي أو الممرّضة قبل استعمال دوبيكسنت:</p><p dir="RTL">دوبيكسنت <strong>ليس دواء إنقاذ</strong> ولا ينبغي استعماله لعلاج نوبة ربو مفاجئة.</p><p dir="RTL"><u>الارتكاسات التحسسيّة</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يسبّب دوبيكسنت بشكل نادر جدًا تأثيرات جانبيّة خطيرة تتضمّن ارتكاسات تحسسيّة (فرط حساسيّة) وردّ فعل تأقيًّا ووذمة وعائية. يُمكِن أن تحدث هذه التفاعلات خلال دقائق وحتى سبعة أيام بعد استعمال دوبيكسنت. يجب عليك أن تنتبه إلى إشارات هذه الحالات (أيّ مشاكل في التنفّس، تورّم الوجه أو الشفتيْن أو الفم أو الحلق أو اللسان، إغماء، دوار، الشعور بدوخة (انخفاض ضغط الدم)، حمى، شعور عام بالتوعّك، تورّم الغدد الليمفاويّة، شرى، حكّة، ألم في المفاصل، طفح جلدي) وأنت تأخذ دوبيكسنت. هذه الإشارات مذكورة في فقرة &quot;التأثيرات الجانبيّة الخطيرة&quot; في القسم 4.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقّف عن استعمال دوبيكسنت وأعلم طبيبك أو اطلب مساعدة طبيّة طارئة إذا لاحظت أيّ إشارات ارتكاس تحسسيّ.</p><p dir="RTL"><u>فرط الحمضات</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرًا ما يُصاب المرضى الذين يأخذون دواء للربو بالتهاب في الأوعية الدمويّة أو الرئتين بسبب ارتفاع عدد بعض كريات الدم البيضاء (فرط الحمضات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من غير المعروف ما إذا كان السبب يعود إلى دوبيكسنت. يحصل هذا عادة ولكن ليس دائمًا لدى الأشخاص الذين يأخذون دواء ستيرويديًا يتمّ إيقافه أو يتمّ تخفيض جرعته.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلم طبيبك على الفور إذا أصبت بمجموعة من العوارض مثل مرض يشبه الانفلوانزا أو شعور بالوخز أو الخدر في الذراعين أو الساقين أو تفاقم العوارض الرئويّة و/أو الطفح.&nbsp;</p><p dir="RTL"><u>العدوى الطفيليّة (الطفيليّات المعويّة)</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يُضعف دوبيكسنت مقاومتك تجاه حالات العدوى التي تسبّبها الطفيليّات. إذا كنت مصابًا بعدوى طفيليّة يجب أن تُعالج قبل أن تبدأ العلاج بدوبيكسنت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق مع الطبيب إذا كنت مصابًا بإسهال وغازات واضطرابات في المعدة وبراز دهني وتجفاف مما يمكن أن يكون إشارة على عدوى طفيليّة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعيش في منطقة تكون فيها حالات العدوى هذه شائعة أو إذا كنت تسافر إلى منطقة كهذه، تحقق مع طبيبك.</p><p dir="RTL"><u>الربو</u></p><p dir="RTL">إذا كنت مصابًا بالربو وكنت تأخذ أدوية ربو، لا تغيّر أو توقف دواء الربو الذي تأخذه بدون التحدّث إلى طبيبك. تحدّث إلى طبيبك قبل أن توقف دوبيكسنت أو إذا بقي الربو الذي تعاني منه غير متحكّم به أو إذا تفاقم في خلال العلاج بهذا الدواء.&nbsp;</p><p dir="RTL"><u>مشاكل العينين </u></p><p dir="RTL">تحدّث إلى طبيبك إذا أصبت بمشاكل جديدة في العينين أو إذا تفاقمت مشاكلك في العينين، بما في ذلك ألم العين أو التغييرات في الرؤية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنّ سلامة دوبيكسنت ومنافعه غير معروفة بعد لدى الأطفال المصابين بالتهاب الجلد التأتبي ما دون السادسة من العمر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنّ سلامة دوبيكسنت ومنافعه غير معروفة بعد لدى الأطفال المصابين بالربو ما دون الثانية عشرة من العمر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى ودوبيكسنت</strong></p><p dir="RTL">أعلم الطبيب أو الصيدلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستعمل أو استعملت مؤخّرًا أو قد تستعمل أيّ أدوية أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تلقّيت لقاحًا مؤخّرًا أو كنت ستتلقّى لقاحًا.&nbsp;</p><p dir="RTL"><strong>أدوية أخرى للربو</strong></p><p dir="RTL">لا توقف أدوية الربو التي تأخذها أو تخفف جرعتها إلاّ إذا طلب الطبيب ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب إيقاف هذه الأدوية (بخاصة الأدوية المسمّاة <em>الستيرويدات القشرية</em>) بشكل تدريجيّ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يتمّ هذا تحت الرقابة المباشرة لطبيبك وحسب تجاوبك مع دوبيكسنت.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً أو تعتقدين نفسك حاملاً أو كنت تنوين الحمل، استشيري طبيبك قبل استعمال هذا الدواء. إنّ تأثيرات هذا الدواء لدى النساء الحوامل غير معروفة؛ لذلك يُفضّل تفادي استعمال دوبيكسنت في خلال فترة الحمل إلاّ إذا أوصى الطبيب باستعماله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُرضعين أو كنتِ تنوين الإرضاع، تحدّثي إلى طبيبك قبل استعمال هذا الدواء. يجب أن تقررا أنت وطبيبك إذا كنت ستُرضعين أو ستستعملين دوبيكسنت. لا يجدر بك فعل الأمرين معًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قيادة السيّارات واستعمال الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثّر دوبيكسنت على قدرتك على القيادة وعلى استعمال الآلات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي دوبيكسنت على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقلّ من 1 ملمول من الصوديوم (23 ملغ) في كلّ جرعة من 200 ملغ، أي أنّه &quot;خالٍ من الصوديوم&quot; أساسًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعمل هذا الدواء دائمًا حسب تعليمات الطبيب أو الصيدلي تمامًا. تحقق مع الطبيب أو الصيدلي إذا لم تكن متأكّدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يُعطى دوبيكسنت</strong></p><p dir="RTL">يُعطى دوبيكسنت عن طريق الحقن تحت الجلد (حقن تحت الجلد).</p><p dir="RTL"><strong>كميّة دوبيكسنت التي ستتلقّاها</strong></p><p dir="RTL">سيقرّر طبيبك جرعة دوبيكسنت المناسبة لك.&nbsp;</p><p dir="RTL"><u>الجرعة الموصى بها لدى المراهقين المصابين بالتهاب الجلد التأتبي</u></p><p dir="RTL">ترتكز الجرعة الموصى بها من دوبيكسنت للمراهقين (12 إلى 17 عامًا) المصابين بالتهاب الجلد التأتبي على وزن الجسم:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>وزن جسم المريض</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة الأوّليّة</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعات اللاحقة (مرّة كلّ أسبوعين)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أقلّ من 60 كلغ</p></td><td style="vertical-align:top"><p dir="RTL">400 ملغ (حقنتان من 200 ملغ)</p></td><td style="vertical-align:top"><p dir="RTL">200 ملغ</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">60 كلغ أو أكثر</p></td><td style="vertical-align:top"><p dir="RTL">600 ملغ (حقنتان من 300 ملغ)</p></td><td style="vertical-align:top"><p dir="RTL">300 ملغ</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الجرعة الموصى بها لدى الأطفال المصابين بالتهاب الجلد التأتبي</u></p><p dir="RTL">ترتكز الجرعة الموصى بها من دوبيكسنت للأطفال (6 إلى 11 عام) المصابين بالتهاب الجلد التأتبي على وزن الجسم:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>وزن جسم المريض</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة الأوّليّة</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعات اللاحقة </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من 15 كلغ إلى أقلّ من 60 كلغ</p></td><td style="vertical-align:top"><p dir="RTL">300 ملغ (حقنة من 300 ملغ) في اليوم الأوّل تليها 300 ملغ في اليوم الخامس عشر</p></td><td style="vertical-align:top"><p dir="RTL">300 ملغ <strong>كلّ 4 أسابيع*</strong> ابتداءً من 4 أسابيع بعد جرعة اليوم الخامس عشر</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">60 كلغ أو أكثر</p></td><td style="vertical-align:top"><p dir="RTL">600 ملغ (حقنتان من 300 ملغ)</p></td><td style="vertical-align:top"><p dir="RTL">300 <strong>ملغ كلّ أسبوعيْن</strong></p></td></tr></tbody></table><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">* يمكن زيادة الجرعة حتّى 200 ملغ كلّ أسبوعيْن بحسب رأي الطبيب.</p><p dir="RTL"><u>الجرعة الموصى بها لدى المرضى البالغين والمراهقين المصابين بالربو (12 عامًا وما فوق)</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">لأغلبيّة المرضى المصابين بالربو الحاد، تبلغ جرعة دوبيكسنت الموصى بها:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة أوّلية من 400 ملغ (على حقنتين من 200 ملغ)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تليها جرعة من 200 ملغ مرّة كلّ أسبوعين عن طريق الحقن تحت الجلد.</p><p dir="RTL">للمرضى المصابين بالربو الحاد ويأخذون ستيرويدات قشريّة عن طريق الفم أو للمرضى المصابين بربو حاد وبالتهاب الجلد التأتبي المصاحب المعتدل إلى الشديد أو للبالغين المصابين بالتهاب الأنف والجيوب المزمن مع داء السّلائل الأنفي المصاحب، تبلغ جرعة دوبيكسنت الموصى بها:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة أوّلية من 600 ملغ (على حقنتين من 300 ملغ)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تليها جرعة من 300 ملغ مرّة كلّ أسبوعين عن طريق الحقن تحت الجلد.</p><p dir="RTL"><strong>حقن</strong><strong> </strong><strong>دوبيكسنت </strong></p><p dir="RTL">يُعطى دوبيكسنت عن طريق الحقن تحت الجلد (حقن تحت الجلد). يجب أن تقررا أنت وطبيبك أو الممرضة إذا كان يجدر بك حقن دوبيكسنت بنفسك.</p><p dir="RTL">قبل حقن دوبيكنست بنفسك، يجب أن يكون قد درّبك طبيبك أو ممرّضتك كما يجب. يمكن أيضًا أن يعطيك مقدّم رعاية الحقنة بعد تدريب مناسب من قبل طبيب أو ممرّضة.&nbsp; &nbsp;</p><p dir="RTL">تحتوي كلّ محقنة معبّأة مسبقًا على جرعة واحدة من دوبيكسنت (200 ملغ). لا ترجّ المحقنة المعبّأة مسبقًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إقرأ &quot;تعليمات الاستعمال&quot; الخاصة بالمحقنة المعبّأة مسبقًا بدقّة قبل استعمال دوبيكسنت.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استعملت كميّة من دوبيكسنت أكثر مما يجب</strong></p><p dir="RTL">إذا استعملت كميّة دوبيكسنت أكثر مما يجب أو إذا تمّ إعطاؤك الجرعة في موعد مبكر جدًا، تحدّث إلى الطبيب أو الصيدليّ أو الممرّضة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استعمال دوبيكسنت</strong></p><p dir="RTL">إذا نسيت حقن جرعة من دوبيكسنت، تحدّث إلى الطبيب أو الصيدلي أو الممرّضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استعمال دوبيكسنت</strong></p><p dir="RTL">لا تتوقف عن استعمال دوبيكسنت بدون التحدّث إلى طبيبك أوّلاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أيّ أسئلة إضافيّة حول استعمال هذا الدواء، اطرحها على الطبيب أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل الأدوية كلّها، يمكن أن يسبّب هذا الدواء تأثيرات جانبيّة لا تصيب المرضى كلّهم.</p><p dir="RTL">يمكن أن يسبّب دوبيكسنت تأثيرات جانبيّة خطيرة تتضمّن ارتكاسات تحسسيّة نادرة جدًا (فرط حساسيّة)، تتضمّن ردّ فعل تأقيًّا؛ قد تتضمّن إشارات الارتكاس التحسسيّ أو رد الفعل التأقيّ ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفّس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الوجه أو الشفتيْن أو الفم أو الحلق أو اللسان (وذمة وعائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء، دوار، الشعور بدوخة (انخفاض ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور عام بالتوعّك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الغدد الليمفاوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكّة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي&nbsp;&nbsp;</p><p dir="RTL">إذا أصبت بارتكاس تحسسيّ، توقّف عن استعمال دوبيكسنت وتحدّث إلى طبيبك عل الفور.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>تأثيرات جانبيّة أخرى</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>تأثيرات جانبيّة شائعة جدًا </strong>(قد تصيب أكثر من شخص من أصل 10 أشخاص) في التهاب الجلد التأتبي والربو:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتكاسات في موقع الحقن (أيّ احمرار وتورّم وحكّة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبيّة شائعة </strong>(قد تصيب لغاية شخص من أصل 10 أشخاص) في التهاب الجلد التأتبي فقط:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف واحمرار وحكّة في العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكّة واحمرار وتورّم في الجفن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قروح باردة (على الشفتين والجلد)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبيّة نادرة </strong>(قد تصيب لغاية شخص من أصل 100 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب سطح العين، مع رؤية ضبابيّة أحيانًا (التهاب القرنية، التهاب القرنية التقرحي)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثيرات جانبيّة غير معروفة</strong></p><p dir="RTL">تم الإبلاغ عن التأثيرات الجانبيّة الآتية منذ تسويق دوبيكسنت ولكن معدّل حصولها غير معروف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبیة</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة</strong><strong> </strong><strong>العربیة</strong><strong> </strong><strong>السعودیة</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز</strong><strong> </strong><strong>الوطني</strong><strong> </strong><strong>للتیقظ</strong><strong>:</strong></p><p dir="RTL"><strong>مركز الاتصال بهيئة الغذاء والدواء</strong><strong>: </strong>19999</p><p dir="LTR">npc.drug@sfda.gov.sa <strong>: </strong><strong>البرید</strong><strong> </strong><strong>الإلكتروني</strong></p><p dir="LTR">https://ade.sfda.gov.sa/<strong> : </strong><strong>الموقع</strong><strong> </strong><strong>الإلكتروني</strong></p><p dir="LTR">KSA_Pharmacovigilance@sanofi.com <strong>: </strong><strong>سانوفي-التيقظ الدوائي</strong></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن نظر الأطفال ومتناولهم.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحيّة المذكور على اللصاقة وعلبة الكرتون بعد كلمة EXP. يشير تاريخ انقضاء الصلاحيّة إلى اليوم الأخير من الشهر المذكور.&nbsp;</p><p dir="RTL">احفظ الدواء في البرّاد (بين درجتين مئويّتين و8 درجات مئويّة). عند الضرورة، يمكن حفظ المحاقن المعبّأة مسبقًا في حرارة الغرفة لغاية 25 درجة مئويّة لمدّة 14 يومًا كحد أقصى. لا تحفظه في درجة حرارة تتجاوز 25 درجة مئويّة. إذا كنت تحتاج إلى إخراج علبة الكرتون بشكل دائم من البرّاد، دوّن تاريخ الإخراج في المكان المخصص لذلك على علبة الكرتون الخارجيّة، واستعمل دوبيكسنت في غضون 14 يومًا.</p><p dir="RTL">إحفظ الدواء في علبة الكرتون الأصليّة لحمايته من النور.&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء إذا لاحظت أنّه عكر أو تغيّر لونه أو فيه جزيئات.</p><p dir="RTL">لا تقم برمي أيّ أدوية في مياه الصرف الصحي أو مع النفايات المنزليّة. اسأل الطبيب أو الصيدلي أو الممرضة عن كيفيّة التخلّص من الأدوية التي لم تعد تستعملها، فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي دوبيكسنت</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفاعلة هي دوبيلوماب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي كلّ محقنة معبّأة مسبقًا على 200 ملغ من الدوبيلوماب في 1.14<strong> </strong>مل من محلول الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكوّنات الأخرى هي هيدروكلورايد الأرجينين، هيستيدين، بوليسوربات 80 (E433)، أسيتات الصوديوم، حمض الخليك الجليدي (E260)، سكروز، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>كيف هو شكل دوبيكسنت ومحتويات العلبة</strong></p><p dir="RTL" style="text-align:right">دوبيكسنت هو محلول صافٍ إلى برّاق بعض الشيء، عديم اللون إلى أصفر باهت يأتي في محقنة زجاجية معبّأة مسبقًا.</p><p dir="RTL" style="text-align:right">يأتي دوبيكسنت على شكل محاقن معبّأة مسبقًا من 200 ملغ في علب تحتوي على محقنة معبّأة مسبقًا أو على محقنتيْن معبّأتيْن مسبقًا أو في علبة تحتوي على 3 (3 علب من 1) أو 6 (3 علب من 2) محاقن معبّأة مسبقًا.</p><p dir="RTL" style="text-align:right">قد لا تكون أحجام العلب كلّها مسوّقة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p><strong>&nbsp;</strong>sanofi-aventis groupe</p><p>54, rue La Bo&eacute;tie</p><p>75008 Paris</p><p>France</p><p>&nbsp;</p><p><strong>المصنّع</strong></p><p>SANOFI WINTHROP INDUSTRIE<br />1051 Boulevard Industriel,</p><p dir="RTL">76580 LE TRAIT,</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير 2021.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dupixent 200 mg solution for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dupilumab 200 mg solution for injection in pre-filled syringe

Each single-use pre-filled syringe contains 200 mg of dupilumab in 1.14 ml solution (175 mg/ml).

Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)

Clear to slightly opalescent, colourless to pale yellow sterile solution, which is free from visible particulates, with a pH of approximately 5.9.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Atopic dermatitis</u></p><p>&nbsp;</p><p><em>Adults and adolescents</em></p><p>Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents12 years and older who are candidates for systemic therapy.</p><p>&nbsp;</p><p><em>Children 6 to 11 years of age</em></p><p>Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.</p><p>&nbsp;</p><p><u>Asthma</u></p><p>&nbsp;</p><p>Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised FeNO (see section 5.1), who are inadequately controlled with high dose ICS plus another medicinal product for maintenance treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Treatment should be initiated by healthcare professionals experienced in the diagnosis and treatment of conditions for which dupilumab is indicated (see section 4.1).</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Atopic Dermatitis</u></em></p><p><em>&nbsp;</em></p><p><em>Children and Adolescents (6 to 17 years of age)</em></p><p>The recommended dose of dupilumab for children and adolescents 6 to 17 years of age is specified in Table 1.</p><p>&nbsp;</p><p>Table 1: Dose of dupilumab for subcutaneous administration for children and adolescents 6 years to 17 years of age with atopic dermatitis</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body Weight</strong></p></td><td style="vertical-align:top"><p><strong>Initial Dose</strong></p></td><td style="vertical-align:top"><p><strong>Subsequent Doses</strong></p></td></tr><tr><td style="vertical-align:top"><p>15 to less than 30 kg</p></td><td style="vertical-align:top"><p>600 mg (two 300 mg injections)</p></td><td style="vertical-align:top"><p>300 mg every 4 weeks (Q4W)</p></td></tr><tr><td style="vertical-align:top"><p>30 to less than 60 kg</p></td><td style="vertical-align:top"><p>400 mg (two 200 mg injections)</p></td><td style="vertical-align:top"><p>200 mg every other week (Q2W)</p></td></tr><tr><td style="vertical-align:top"><p>60 kg or more</p></td><td style="vertical-align:top"><p>600 mg (two 300 mg injections)</p></td><td style="vertical-align:top"><p>300 mg every other week (Q2W)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Adults</em></p><p>The recommended dose of dupilumab for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week administered as subcutaneous injection.</p><p>&nbsp;</p><p>Dupilumab can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas.</p><p>&nbsp;</p><p>Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment for atopic dermatitis. Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks. If dupilumab treatment interruption becomes necessary, patients can still be successfully re-treated.</p><p>&nbsp;</p><p><em><u>Asthma</u></em></p><p><em>&nbsp;</em></p><p>The recommended dose of dupilumab for adults and adolescents (12 years of age and older) is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An initial dose of 400 mg (two 200 mg injections), followed by 200 mg given every other week administered as subcutaneous injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients with severe asthma and who are on oral corticosteroids or for patients with severe asthma and co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid severe chronic rhinosinusitis with nasal polyposis, an initial dose of 600 mg (two 300 mg injections), followed by 300 mg every other week administered as subcutaneous injection.</p><p>&nbsp;</p><p>Patients receiving concomitant oral corticosteroids may reduce their steroid dose once clinical improvement with dupilumab has occurred (see section 5.1). Steroid reductions should be accomplished gradually (see section 4.4).</p><p>&nbsp;</p><p>Dupilumab is intended for long-term treatment. The need for continued therapy should be considered at least on an annual basis as determined by physician assessment of the patient&rsquo;s level of asthma control.</p><p>&nbsp;</p><p><u>Missed dose</u></p><p>&nbsp;</p><p>If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly (&ge; 65 years)</em></p><p>No dose adjustment is recommended for elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is needed in patients with mild or moderate renal impairment. Very limited data are available in patients with severe renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No data are available in patients with hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Body weight</em></p><p>No dose adjustment for body weight is recommended for patients with asthma 12 years of age and older or in adults with atopic dermatitis (see section 5.2).</p><p>&nbsp;</p><p>For patients 6 to 17 years of age with atopic dermatitis, the recommended dose is 300 mg Q4W (15 kg to &lt;30 kg), 200 mg Q2W (30 kg to &lt;60 kg), and 300 mg Q2W (&ge;60 kg).</p><p>&nbsp;</p><p><em>Paediatric patients</em></p><p>The safety and efficacy of dupilumab in children with atopic dermatitis below the age of 6 years have not been established (see section 5.2). No data are available.</p><p>&nbsp;</p><p>The safety and efficacy of dupilumab in children with severe asthma below the age of 12 years have not been established (see section 5.2). No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Subcutaneous use</p><p>&nbsp;</p><p>Dupilumab is administered by subcutaneous injection into the thigh or abdomen, except for the 5 cm around the navel. If somebody else administers the injection, the upper arm can also be used.</p><p>&nbsp;</p><p>For the initial 400 mg dose, two 200 mg injections should be administered consecutively in different injection sites.</p><p>&nbsp;</p><p>It is recommended to rotate the injection site with each injection. Dupilumab should not be injected into skin that is tender, damaged or has bruises or scars.</p><p>&nbsp;</p><p>A patient may self-inject dupilumab or the patient&#39;s caregiver may administer dupilumab if their healthcare professional determines that this is appropriate. Proper training should be provided to patients and/or caregivers on the preparation and administration of dupilumab prior to use according to the Instructions for Use (IFU) section in the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dupilumab should not be used to treat acute asthma symptoms or acute exacerbations. Dupilumab should not be used to treat acute bronchospasm or status asthmaticus.</p><p>&nbsp;</p><p>Systemic, topical, or inhaled corticosteroids should not be discontinued abruptly upon initiation of therapy with dupilumab. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be&nbsp;</p><p>associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.</p><p>&nbsp;</p><p>Biomarkers of type 2 inflammation may be suppressed by systemic corticosteroid use. This should be taken into consideration to determine type 2 status in patients taking oral corticosteroids (see section 5.1).</p><p>&nbsp;</p><p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>If a systemic hypersensitivity reaction (immediate or delayed) occurs, administration of dupilumab should be discontinued immediately and appropriate therapy initiated. Very rare cases of serum sickness/serum sickness-like reactions have been reported in the atopic dermatitis development program following the administration of dupilumab. Anaphylactic reaction has been reported very rarely in the asthma development program following the administration of dupilumab (section 4.8).</p><p>&nbsp;</p><p><u>Eosinophilic conditions</u></p><p>&nbsp;</p><p>Cases of eosinophilic pneumonia and cases of vasculitis consistent with eosinophilic granulomatosis with polyangiitis have been reported with dupilumab in adult patients who participated in the asthma development program. Physicians should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis, conditions which are often treated with systemic corticosteroid therapy. These events usually, but not always, may be associated with the reduction of oral corticosteroid therapy.</p><p>&nbsp;</p><p><u>Helminth infection</u></p><p>&nbsp;</p><p>Patients with known helminth infections were excluded from participation in clinical studies. Dupilumab may influence the immune response against helminth infections by inhibiting IL-4/IL-13 signaling. Patients with pre-existing helminth infections should be treated before initiating dupilumab. If patients become infected while receiving treatment with dupilumab and do not respond to anti- helminth treatment, treatment with dupilumab should be discontinued until infection resolves.</p><p>&nbsp;</p><p><u>Conjunctivitis related events</u></p><p>&nbsp;</p><p>Patients treated with dupilumab who develop conjunctivitis that does not resolve following standard treatment should undergo ophthalmological examination (section 4.8).</p><p>&nbsp;</p><p><u>Atopic dermatitis patients with comorbid asthma</u></p><p>&nbsp;</p><p>Patients on dupilumab for moderate-to-severe atopic dermatitis who also have comorbid asthma should not adjust or stop their asthma treatments without consultation with their physicians. Patients with comorbid asthma should be monitored carefully following discontinuation of dupilumab.</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p>&nbsp;</p><p>Live and live attenuated vaccines should not be given concurrently with dupilumab as clinical safety and efficacy has not been established. Immune responses to TdaP vaccine and meningococcal polysaccharide vaccine were assessed, see section 4.5. It is recommended that patients should be brought up to date with live and live attenuated immunisations in agreement with current immunisation guidelines prior to treatment with dupilumab.</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per 200 mg dose, i.e. essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immune responses to vaccination were assessed in a study in which patients with atopic dermatitis were treated once weekly for 16 weeks with 300 mg of dupilumab. After 12 weeks of dupilumab administration, patients were vaccinated with a Tdap vaccine (T cell-dependent), and a meningococcal polysaccharide vaccine (T cell-independent) and immune responses were assessed 4 weeks later.</p><p>Antibody responses to both tetanus vaccine and meningococcal polysaccharide vaccine were similar in dupilumab-treated and placebo-treated patients. No adverse interactions between either of the non-live vaccines and dupilumab were noted in the study.</p><p>&nbsp;</p><p>Therefore, patients receiving dupilumab may receive concurrent inactivated or non-live vaccinations. For information on live vaccines see section 4.4.</p><p>&nbsp;</p><p>In a clinical study of AD patients, the effects of dupilumab on the pharmacokinetics (PK) of CYP substrates were evaluated. The data gathered from this study did not indicate clinically relevant effects of dupilumab on CYP1A2, CYP3A, CYP2C19, CYP2D6, or CYP2C9 activity.</p><p>&nbsp;</p><p>An effect of dupilumab on the PK of co-administered medications is not expected. Based on the population analysis, commonly co-administered medications had no effect on dupilumab pharmacokinetics on patients with moderate to severe asthma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are limited amount of data from the use of dupilumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>Dupilumab should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether dupilumab is excreted in human milk or absorbed systemically after ingestion. A decision must be made whether to discontinue breast-feeding or to discontinue dupilumab therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Animal studies showed no impairment of fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dupilumab has no or negligible influence on the ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Atopic dermatitis</u></p><p>&nbsp;</p><p>Adults with atopic dermatitis</p><p>&nbsp;</p><p><em><u>Summary of the safety profile</u></em></p><p><em>&nbsp;</em></p><p>The most common adverse reactions were injection site reactions, conjunctivitis, blepharitis, and oral herpes. Very rare cases of serum sickness/serum sickness-like reactions have been reported in the atopic dermatitis development program (see section 4.4).</p><p>&nbsp;</p><p>In the monotherapy studies, the proportion of patients who discontinued treatment due to adverse events was 1.9 % of the placebo group, 1.9 % of the dupilumab 300 mg Q2W group, 1.5 % of the dupilumab 300 mg QW group. In the concomitant TCS study, the proportion of patients who discontinued treatment due to adverse events was 7.6 % of the placebo + TCS group, 1.8 % of the dupilumab 300 mg Q2W + TCS group, and 2.9 % of the dupilumab 300 mg QW + TCS group.</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p><em>&nbsp;</em></p><p>The safety of dupilumab was evaluated in four randomized, double-blind, placebo-controlled studies and one dose-ranging study in patients with moderate-to-severe atopic dermatitis. In these 5 trials, 1,689 subjects were treated with subcutaneous injections of dupilumab, with or without concomitant topical corticosteroids (TCS). A total of 305 patients were treated with dupilumab for at least 1 year.</p><p>&nbsp;</p><p>Listed in Table 2 are adverse reactions observed in atopic dermatitis clinical trials presented by system organ class and frequency, using the following categories: very common (&ge; 1/10); common (&ge; 1/100 to</p><p>&lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 2: List of adverse reactions in atopic dermatitis</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System</strong></p><p><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and</em></p><p><em>infestations</em></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Conjunctivitis</p><p>Oral herpes</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Serum sickness/serum sickness-like reactions</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Conjunctivitis allergic</p><p>Eye pruritus Blepharitis</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration</em></p><p><em>site conditions</em></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Injection site reactions</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Adolescents with atopic dermatitis (12 to 17 years of age)</p><p>&nbsp;</p><p>The safety of dupilumab was assessed in a study of 250 patients 12 to 17 years of age with moderate- to-severe atopic dermatitis (AD-1526). The safety profile of dupilumab in these patients followed through week 16 was similar to the safety profile from studies in adults with atopic dermatitis.</p><p>&nbsp;</p><p>The long-term safety of dupilumab was assessed in an open-label extension study in patients 12 to</p><p>17&nbsp;&nbsp;&nbsp; years of age with moderate-to-severe atopic dermatitis (AD-1434). The safety profile of&nbsp;</p><p>dupilumab in patients followed through week 52 was similar to the safety profile observed at week 16 in AD-1526 study. The long-term safety profile of dupilumab observed in adolescents was consistent with that seen in adults with atopic dermatitis.</p><p>&nbsp;</p><p>Paediatric patients with atopic dermatitis (6 to 11 years of age)</p><p>&nbsp;</p><p>The safety of dupilumab was assessed in a trial of 367 patients 6 to 11 years of age with severe atopic dermatitis (AD-1652). The safety profile of dupilumab + TCS in these patients through Week 16 was similar to the safety profile from studies in adults and adolescents with atopic dermatitis.</p><p>&nbsp;</p><p>The long-term safety of dupilumab + TCS was assessed in an open-label extension study of 368 subjects 6 to 11 years of age with atopic dermatitis (AD-1434). Among patients who entered this study, 110 (29.9%) had moderate and 72 (19.6%) had severe atopic dermatitis at the time of enrolment in study AD-1434. The safety profile of dupilumab + TCS in subjects followed through Week 52 was similar to the safety profile observed at Week 16 in AD-1652. The long-term safety profile of dupilumab + TCS observed in paediatric patients was consistent with that seen in adults and adolescents with atopic dermatitis.</p><p>&nbsp;</p><p><u>Asthma</u></p><p>&nbsp;</p><p><em><u>Summary of the safety profile</u></em></p><p><em>&nbsp;</em></p><p>The most common adverse reaction was injection site erythema. Anaphylactic reaction has been reported very rarely in the asthma development program (see section 4.4).</p><p>&nbsp;</p><p>In DRI12544 and QUEST studies, the proportion of patients who discontinued treatment due to adverse events was 4.3% of the placebo group, 3.2% of the dupilumab 200 mg Q2W group, and 6.1% of the dupilumab 300 mg Q2W group.</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p><em>&nbsp;</em></p><p>A total of 2,888 adult and adolescent patients with moderate-to-severe asthma were evaluated in 3 randomised, placebo-controlled, multicentre trials of 24 to 52 weeks duration (DRI12544, QUEST, and VENTURE). Of these, 2,678 had a history of 1 or more severe exacerbations in the year prior to enrolment despite regular use of medium-to-high dose inhaled corticosteroids plus an additional controller(s) (DRI12544 and QUEST). A total of 210 patients with oral corticosteroid-dependent asthma receiving high-dose inhaled corticosteroids plus up to two additional controllers were enrolled (VENTURE).</p><p>&nbsp;</p><p>Listed in Table 3 are adverse reactions observed in asthma clinical trials presented by system organ class and frequency, using the following categories: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 3: List of adverse reactions in asthma</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System</strong></p><p><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Very common Common Common</p><p>Common</p></td><td style="vertical-align:top"><p>Injection site erythema Injection site oedema Injection site pain</p><p>Injection site pruritus</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions in atopic dermatitis and asthma indications</u></p><p>&nbsp;</p><p><em>Hypersensitivity</em></p><p>Very rare cases of serum sickness/serum sickness-like reactions and anaphylactic reaction have been reported following administration of dupilumab (see section 4.4).</p><p>&nbsp;</p><p><em>Conjunctivitis and related events</em></p><p>Conjunctivitis occurred more frequently in atopic dermatitis patients who received dupilumab. Most patients with conjunctivitis recovered or were recovering during the treatment period. Among asthma patients frequency of conjunctivitis was low and similar between dupilumab and placebo (see section 4.4).</p><p>&nbsp;</p><p><em>Eczema herpeticum</em></p><p>Eczema herpeticum was reported in &lt; 1 % of the dupilumab groups and in &lt; 1 % of the placebo group in the 16-week atopic dermatitis monotherapy studies. In the 52-week atopic dermatitis dupilumab + TCS study, eczema herpeticum was reported in 0.2 % of the dupilumab + TCS group and 1.9 % of the placebo + TCS group.</p><p>&nbsp;</p><p><em>Eosinophilia</em></p><p>Dupilumab-treated patients had a greater mean initial increase from baseline in eosinophil count compared to patients treated with placebo. Eosinophil counts declined to near baseline levels during study treatment.</p><p>&nbsp;</p><p>Treatment-emergent eosinophilia (&ge; 5,000 cells/mcL) was reported in &lt; 2 % of dupilumab-treated patients and &lt; 0.5 % in placebo-treated patients.</p><p>&nbsp;</p><p><em>Infections</em></p><p>In the 16-week atopic dermatitis monotherapy clinical studies, serious infections were reported in 1.0 % of patients treated with placebo and 0.5 % of patients treated with dupilumab. In the 52-week atopic dermatitis CHRONOS study, serious infections were reported in 0.6 % of patients treated with placebo and 0.2 % of patients treated with dupilumab.</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>As with all therapeutic proteins, there is a potential for immunogenicity with dupilumab.</p><p>&nbsp;</p><p>Anti-Drug-Antibodies (ADA) responses were not generally associated with impact on dupilumab exposure, safety, or efficacy.</p><p>&nbsp;</p><p>Approximately 6 % of patients with atopic dermatitis or asthma who received dupilumab 300 mg Q2W for 52 weeks developed ADA to dupilumab; approximately 2 % exhibited persistent ADA responses and approximately 2 % had neutralizing antibodies. Similar results were observed in paediatric patients (6 to 11 years of age) with atopic dermatitis who received dupilumab 200 mg Q2W or 300 mg Q4W for 16 weeks.</p><p>&nbsp;</p><p>Approximately 16% of adolescent patients with atopic dermatitis who received dupilumab 300 mg or 200 mg Q2W for 16 weeks developed antibodies to dupilumab; approximately 3% exhibited persistent ADA responses, and approximately 5% had neutralizing antibodies.</p><p>&nbsp;</p><p>Approximately 9 % of patients with asthma who received dupilumab 200 mg Q2W for 52 weeks developed antibodies to dupilumab; approximately 4 % exhibited persistent ADA responses and approximately 4 % had neutralizing antibodies.</p><p>&nbsp;</p><p>Regardless of age or population, approximately 2 to 4 % of patients in the placebo groups were positive for antibodies to dupilumab; approximately 2 % exhibited persistent ADA response and approximately 1% had neutralizing antibodies.</p><p>Less than 1 % of patients who received dupilumab at approved dosing regimens exhibited high titer ADA responses associated with reduced exposure and efficacy. In addition, there was one patient with serum sickness and one with serum sickness-like reaction (&lt; 0.1 %) associated with high ADA titers (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety profile observed in children and adolescents aged 6 to 17 years in atopic dermatitis clinical trials was similar to that seen in adults.</p><p>&nbsp;</p><p>A total of 107 adolescents aged 12 to 17 years with asthma were enrolled in the 52 week QUEST study. The safety profile observed was similar to that seen in adults.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o SFDA call center : 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sanofi- Pharmacovigilance:<strong> </strong>KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for dupilumab overdose. In the event of overdosage, monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other dermatological preparations, agents for dermatitis, excluding corticosteroids, ATC code: D11AH05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Dupilumab is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. Dupilumab inhibits IL-4 signaling via the Type I receptor (IL-4R&alpha;/&gamma;c), and both IL-4 and IL-13 signaling through the Type II receptor (IL-4R&alpha;/IL-13R&alpha;). IL-4 and IL-13 are major drivers of human type 2 inflammatory disease, such as atopic dermatitis and asthma. Blocking the IL-4/IL-13 pathway with dupilumab in patients decreases many of the mediators of type 2 inflammation.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>In atopic dermatitis clinical trials, treatment with dupilumab was associated with decreases from baseline in concentrations of type 2 immunity biomarkers, such as thymus and activation-regulated chemokine (TARC/CCL17), total serum IgE and allergen-specific IgE in serum. A reduction of lactate dehydrogenase (LDH), a biomarker associated with AD disease activity and severity, was observed with dupilumab treatment.</p><p>&nbsp;</p><p>In asthma clinical trials, dupilumab treatment markedly decreased FeNO and circulating concentrations of eotaxin-3, total IgE, allergen specific IgE, TARC, and periostin in asthma subjects relative to placebo. These reductions in type 2 inflammatory biomarkers were comparable for the</p><p>200 mg Q2W and 300 mg Q2W regimens. These markers were near maximal suppression after 2 weeks of treatment, except for IgE which declined more slowly. These effects were sustained throughout treatment.</p><p><u>Clinical efficacy and safety in atopic dermatitis</u></p><p>&nbsp;</p><p>Adolescents with atopic dermatitis (12 to 17 years of age)</p><p>&nbsp;</p><p>The efficacy and safety of dupilumab monotherapy in adolescent patients was evaluated in a multicentre, randomised, double-blind, placebo-controlled study (AD-1526) in 251 adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis (AD) defined by Investigator&rsquo;s Global Assessment (IGA) score &ge;3 in the overall assessment of AD lesions on a severity scale of 0 to 4, an Eczema Area and Severity Index (EASI) score &ge;16 on a scale of 0 to 72, and a minimum body surface area (BSA) involvement of &ge;10%. Eligible patients enrolled into this study had previous inadequate response to topical medication.</p><p>&nbsp;</p><p>Patients received 1) an initial dose of 400 mg dupilumab (two 200 mg injections) on day 1, followed by 200 mg once every other week (Q2W) for patients with baseline weight of &lt;60 kg or an initial dose of 600 mg dupilumab (two 300 mg injections) on day 1, followed by 300 mg Q2W for patients with baseline weight of &ge; 60 kg; 2) an initial dose of 600 mg dupilumab (two 300 mg injections) on day 1, followed by 300 mg every 4 weeks (Q4W) regardless of baseline body weight; or 3) matching placebo. Dupilumab was administered by subcutaneous (SC) injection. If needed to control intolerable symptoms, patients were permitted to receive rescue treatment at the discretion of the investigator. Patients who received rescue treatment were considered non- responders.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:line
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;z-index:-23243776;
 mso-position-horizontal-relative:page' from="165.6pt,58.05pt" to="167.4pt,58.05pt"
 strokecolor="blue" strokeweight=".46pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="4" height="2" src="file:///C:/Users/sa000712/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />In this study, the mean age was 14.5 years, the median weight was 59.4 kg, 41.0 % were female, 62.5% were White, 15.1% were Asian, and 12.0% were Black. At baseline 46.2% of patients had a baseline IGA score of 3 (moderate AD), 53.8% of patients had a baseline IGA of 4 (severe AD), the mean BSA involvement was 56.5%, and 42.4 % of patients had received prior systemic immunosuppressants. Also at baseline the mean Eczema Area and Severity Index (EASI) score was 35.5, the baseline weekly averaged pruritus Numerical Rating Scale (NRS) was 7.6, the baseline mean SCORing Atopic Dermatitis (SCORAD) score was 70.3, the baseline mean Patient Oriented Eczema Measure (POEM) score was 21.0, and the baseline mean Children Dermatology Life Quality Index (CDLQI) was 13.6. Overall, 92.0% of patients had at least one co-morbid allergic condition; 65.6% had allergic rhinitis, 53.6% had asthma, and 60.8% had food allergies. The co-primary endpoint was the proportion of patients with IGA 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) least a 2-point improvement and the proportion of patients with EASI-75 (improvement of at least 75% in EASI), from baseline to week 16. Other evaluated outcomes included the proportion of subjects with EASI-50 or EASI-90 (improvement of at least 50% or 90% in EASI from baseline respectively), reduction in itch as measured by the peak pruritus NRS, and percent change in the SCORAD scale from baseline to week 16. Additional secondary endpoints included mean change from baseline to week 16 in the POEM and CDLQI scores.</p><p><em>Clinical Response</em></p><p><em>&nbsp;</em></p><p>The efficacy results at week 16 for adolescent atopic dermatitis study are presented in Table 4.</p><p><strong>Table 4: Efficacy results of dupilumab in the adolescent atopic dermatitis study at Week 16 (FAS)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>AD-1526(FAS)<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Dupilumab</strong></p><p><strong>200 mg (&lt;60 kg) and</strong></p><p><strong>300 mg (&ge;60 kg) Q2W</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Patients randomised</em></strong></p></td><td style="vertical-align:top"><p><strong>85</strong><sup>a</sup></p></td><td style="vertical-align:top"><p><strong>82</strong><sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>IGA 0 or 1<sup>b</sup>, % responders<sup>c</sup></p></td><td style="vertical-align:top"><p>2.4%</p></td><td style="vertical-align:top"><p>24.4%</p></td></tr><tr><td style="vertical-align:top"><p>EASI-50, % responders<sup>c</sup></p></td><td style="vertical-align:top"><p>12.9%</p></td><td style="vertical-align:top"><p>61.0%</p></td></tr><tr><td style="vertical-align:top"><p>EASI-75, % responders<sup>c</sup></p></td><td style="vertical-align:top"><p>8.2%</p></td><td style="vertical-align:top"><p>41.5%</p></td></tr><tr><td style="vertical-align:top"><p>EASI-90, % responders<sup>c</sup></p></td><td style="vertical-align:top"><p>2.4%</p></td><td style="vertical-align:top"><p>23.2%</p></td></tr><tr><td style="vertical-align:top"><p>EASI, LS mean % change from baseline (+/-SE)</p></td><td style="vertical-align:top"><p>-23.6%</p><p>(5.49)</p></td><td style="vertical-align:top"><p>-65.9%</p><p>(3.99)</p></td></tr><tr><td style="vertical-align:top"><p>SCORAD, LS mean % change from baseline (+/- SE)</p></td><td style="vertical-align:top"><p>-17.6%</p><p>(3.76)</p></td><td style="vertical-align:top"><p>-51.6%</p><p>(3.23)</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus NRS, LS mean % change from baseline (+/- SE)</p></td><td style="vertical-align:top"><p>-19.0%</p><p>(4.09)</p></td><td style="vertical-align:top"><p>-47.9%</p><p>(3.43)</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus NRS (<u>&gt;</u>4-point improvement), % responders<sup>c</sup></p></td><td style="vertical-align:top"><p>4.8%</p></td><td style="vertical-align:top"><p>36.6%</p></td></tr><tr><td style="vertical-align:top"><p>BSA LS mean % change from baseline</p><p>(+/- SE)</p></td><td style="vertical-align:top"><p>-11.7%</p><p>(2.72)</p></td><td style="vertical-align:top"><p>-30.1%</p><p>(2.34)</p></td></tr><tr><td style="vertical-align:top"><p>CDLQI, LS mean change from baseline</p><p>(+/-SE)</p></td><td style="vertical-align:top"><p>-5.1</p><p>(0.62)</p></td><td style="vertical-align:top"><p>-8.5</p><p>(0.50)</p></td></tr><tr><td style="vertical-align:top"><p>CDLQI, (&ge;6-point improvement), % responders</p></td><td style="vertical-align:top"><p>19.7%</p></td><td style="vertical-align:top"><p>60.6%</p></td></tr><tr><td style="vertical-align:top"><p>POEM, LS mean change from baseline (+/- SE)</p></td><td style="vertical-align:top"><p>-3.8</p><p>(0.96)</p></td><td style="vertical-align:top"><p>-10.1</p><p>(0.76)</p></td></tr><tr><td style="vertical-align:top"><p>POEM, (<strong>&ge;</strong>6-point improvement), % responders</p></td><td style="vertical-align:top"><p>9.5%</p></td><td style="vertical-align:top"><p>63.4%</p></td></tr></tbody></table><p><sup>a</sup> Full Analysis Set (FAS) includes all patients randomised.</p><p><sup>b</sup> Responder was defined as a subject with IGA 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) with a reduction of &ge;2 points on a 0-4 IGA scale.</p><p><sup>c</sup> Patients who received rescue treatment or with missing data were considered as non-responders (58.8% and 20.7% in the placebo and dupilumab arms, respectively).</p><p>All p &ndash;values &lt;0.0001</p><p>&nbsp;</p><p>A larger percentage of patients randomised to placebo needed rescue treatment (topical corticosteroids, systemic corticosteroids, or systemic non-steroidal immunosuppressants) as compared to the dupilumab group (58.8% and 20.7%, respectively).</p><p>&nbsp;</p><p>A significantly greater proportion of patients randomised to dupilumab achieved a rapid improvement in the pruritus NRS compared to placebo (defined as <u>&gt;</u>4-point improvement as early as week 4; nominal p&lt;0.001) and the proportion of patients responding on the pruritus NRS continued to increase through the treatment period (see Figure 1). The improvement in pruritus NRS occurred in conjunction with the improvement of objective signs of atopic dermatitis.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image6.png" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;left:0;text-align:left;margin-left:71.95pt;
  margin-top:34.2pt;width:276.1pt;height:233.65pt;z-index:12;visibility:visible;
  mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
  mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/sa000712/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="368" height="312" src="file:///C:/Users/sa000712/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Figure 1: Proportion of adolescent patients with &ge;4-point improvement on the pruritus NRS in AD-1526 study<sup>a</sup> (FAS)<sup>b</sup></p><p><sup>a</sup> In the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered non-responders.</p><p><sup>b</sup> Full Analysis Set (FAS) includes all subjects randomised.</p><p>&nbsp;</p><p>The dupilumab group significantly improved patient-reported symptoms, the impact of AD on sleep and health-related quality of life as measured by POEM, SCORAD, and CDLQI scores at 16 weeks compared to placebo.</p><p>&nbsp;</p><p>The long-term efficacy of dupilumab in adolescent patients with moderate-to-severe AD who had participated in previous clinical trials of dupilumab was assessed in open-label extension study (AD- 1434). Efficacy data from this study suggests that clinical benefit provided at week 16 was sustained through week 52.</p><p>&nbsp;</p><p>Paediatrics (6 to 11 years of age)</p><p>&nbsp;</p><p>The efficacy and safety of dupilumab in paediatric patients concomitantly with TCS was evaluated in a multicentre, randomised, double-blind, placebo-controlled study (AD-1652) in 367 subjects 6 to 11 years of age, with AD defined by an IGA score of 4 (scale of 0 to 4), an EASI score &ge;21 (scale of 0 to 72), and a minimum BSA involvement of &ge;15%. Eligible patients enrolled into this trial had previous inadequate response to topical medication. Enrollment was stratified by baseline weight (&lt;30 kg; &ge;30 kg).</p><p>&nbsp;</p><p>Patients in the dupilumab Q2W + TCS group with baseline weight of &lt;30 kg received an initial dose of 200 mg on Day 1, followed by 100 mg Q2W from Week 2 to Week 14, and patients with baseline weight of &ge;30 kg received an initial dose of 400 mg on Day 1, followed by 200 mg Q2W from week 2 to week 14. Patients in the dupilumab Q4W + TCS group received an initial dose of 600 mg on Day 1, followed by 300 mg Q4W from week 4 to week 12, regardless of weight. Patients were permitted to receive rescue treatment at the discretion of the investigator. Patients who received rescue treatment were considered non-responders.</p><p>&nbsp;</p><p>In this study, the mean age was 8.5 years, the median weight was 29.8 kg, 50.1% of patients were female, 69.2% were White, 16.9% were Black, and 7.6% were Asian. At baseline, the mean BSA involvement was 57.6%, and 16.9% had received prior systemic non-steroidal immunosuppressants. Also, at baseline the mean EASI score was 37.9, and the weekly average of daily worst itch score was</p><p>7.8 on a scale of 0-10, the baseline mean SCORAD score was 73.6, the baseline POEM score was</p><p>20.9, and the baseline mean CDLQI was 15.1. Overall, 91.7% of subjects had at least one co-morbid allergic condition; 64.4% had food allergies, 62.7% had other allergies, 60.2% had allergic rhinitis, and 46.7% had asthma.</p><p>&nbsp;</p><p>The primary endpoint was the proportion of patients with an IGA 0 (clear) or 1 (almost clear) at week 16. Other evaluated outcomes included the proportion of patients with EASI-75 or EASI-90 (improvement of at least 75% or 90% in EASI from baseline, respectively), percent change in EASI</p><p>score from baseline to week 16, and reduction in itch as measured by the peak pruritus NRS (&ge;4-point improvement). Additional secondary endpoints included mean change from baseline to week 16 in the POEM and CDLQI scores.</p><p>&nbsp;</p><p><em>Clinical Response</em></p><p><em>&nbsp;</em></p><p>Table 5 presents the results by baseline weight strata for the approved dose regimens.</p><p>&nbsp;</p><p>TABLE 5: Efficacy Results of Dupilumab with Concomitant TCS in AD-1652 at Week 16 (FAS)<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dupilumab 300 mg Q4W<sup>d</sup></strong></p><p><strong>+ TCS</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>+TCS</strong></p></td><td style="vertical-align:top"><p><strong>Dupilumab 200 mg Q2W<sup>e</sup></strong></p><p><strong>+ TCS</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>+ TCS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>(N=61)</strong></p></td><td style="vertical-align:top"><p><strong>(N=61)</strong></p></td><td style="vertical-align:top"><p><strong>(N=59)</strong></p></td><td style="vertical-align:top"><p><strong>(N=62)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&lt;30 kg</strong></p></td><td style="vertical-align:top"><p><strong>&lt;30 kg</strong></p></td><td style="vertical-align:top"><p><strong>&ge;30 kg</strong></p></td><td style="vertical-align:top"><p><strong>&ge;30 kg</strong></p></td></tr><tr><td style="vertical-align:top"><p>IGA 0 or 1<sup>b</sup>, % responders<sup>,c</sup></p></td><td style="vertical-align:top"><p>29.5%</p></td><td style="vertical-align:top"><p>13.1%</p></td><td style="vertical-align:top"><p>39.0%</p></td><td style="vertical-align:top"><p>9.7%</p></td></tr><tr><td style="vertical-align:top"><p>EASI-50, % responders<sup>,c</sup></p></td><td style="vertical-align:top"><p>95.1%</p></td><td style="vertical-align:top"><p>42.6%</p></td><td style="vertical-align:top"><p>86.4%</p></td><td style="vertical-align:top"><p>43.5%</p></td></tr><tr><td style="vertical-align:top"><p>EASI-75, % responders<sup>,c</sup></p></td><td style="vertical-align:top"><p>75.4%</p></td><td style="vertical-align:top"><p>27.9%</p></td><td style="vertical-align:top"><p>74.6%</p></td><td style="vertical-align:top"><p>25.8%</p></td></tr><tr><td style="vertical-align:top"><p>EASI-90, % responders<sup>,c</sup></p></td><td style="vertical-align:top"><p>45.9%</p></td><td style="vertical-align:top"><p>6.6%</p></td><td style="vertical-align:top"><p>35.6%</p></td><td style="vertical-align:top"><p>8.1%</p></td></tr><tr><td style="vertical-align:top"><p>EASI, LS mean % change from baseline (+/-SE)</p></td><td style="vertical-align:top"><p>-84.3%</p><p>(3.08)</p></td><td style="vertical-align:top"><p>-49.1%</p><p>(3.30)</p></td><td style="vertical-align:top"><p>-80.4%</p><p>(3.61)</p></td><td style="vertical-align:top"><p>-48.3%</p><p>(3.63)</p></td></tr><tr><td style="vertical-align:top"><p>SCORAD, LS mean % change</p><p>from baseline (+/- SE)</p></td><td style="vertical-align:top"><p>-65.3%</p><p>(2.87)</p></td><td style="vertical-align:top"><p>-28.9%</p><p>(3.05)</p></td><td style="vertical-align:top"><p>-62.7%</p><p>(3.14)</p></td><td style="vertical-align:top"><p>-30.7%</p><p>(3.28)</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus NRS, LS mean % change from baseline (+/- SE)</p></td><td style="vertical-align:top"><p>-55.1%</p><p>(3.94)</p></td><td style="vertical-align:top"><p>-27.0%</p><p>(4.24)</p></td><td style="vertical-align:top"><p>-58.2%</p><p>(4.01)</p></td><td style="vertical-align:top"><p>-25.0%</p><p>(3.95)</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus NRS (&ge;4-point</p><p>improvement), % responders<sup>,c</sup></p></td><td style="vertical-align:top"><p>54.1%</p></td><td style="vertical-align:top"><p>11.7%</p></td><td style="vertical-align:top"><p>61.4%</p></td><td style="vertical-align:top"><p>12.9%</p></td></tr><tr><td style="vertical-align:top"><p>BSA LS mean change from baseline (+/- SE)</p></td><td style="vertical-align:top"><p>-43.2</p><p>(2.16)</p></td><td style="vertical-align:top"><p>-23.9</p><p>(2.34)</p></td><td style="vertical-align:top"><p>-38.4</p><p>(2.47)</p></td><td style="vertical-align:top"><p>-19.8</p><p>(2.50)</p></td></tr><tr><td style="vertical-align:top"><p>CDLQI, LS mean change from baseline (+/-SE)</p></td><td style="vertical-align:top"><p>-11.5</p><p>(0.69)</p></td><td style="vertical-align:top"><p>-7.2</p><p>(0.76)</p></td><td style="vertical-align:top"><p>-9.8</p><p>(0.63)</p></td><td style="vertical-align:top"><p>-5.6</p><p>(0.66)</p></td></tr><tr><td style="vertical-align:top"><p>CDLQI, (&ge;6-point improvement),</p><p>% responders</p></td><td style="vertical-align:top"><p>81.8%</p></td><td style="vertical-align:top"><p>48.3%</p></td><td style="vertical-align:top"><p>80.8%</p></td><td style="vertical-align:top"><p>35.8%</p></td></tr><tr><td style="vertical-align:top"><p>POEM, LS mean change from baseline (+/- SE)</p></td><td style="vertical-align:top"><p>-14.0</p><p>(0.95)</p></td><td style="vertical-align:top"><p>-5.9</p><p>(1.04)</p></td><td style="vertical-align:top"><p>-13.6</p><p>(0.90)</p></td><td style="vertical-align:top"><p>-4.7</p><p>(0.91)</p></td></tr><tr><td style="vertical-align:top"><p>POEM, (&ge;6-point improvement),</p><p>% responders</p></td><td style="vertical-align:top"><p>81.4%</p></td><td style="vertical-align:top"><p>32.8%</p></td><td style="vertical-align:top"><p>79.3%</p></td><td style="vertical-align:top"><p>31.1%</p></td></tr></tbody></table><p>Full Analysis Set (FAS) includes all patients randomised.</p><p><sup>b</sup> Responder was defined as a patient with an IGA 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;).</p><p><sup>c</sup> Patients who received rescue treatment or with missing data were considered as non-responders.</p><p><sup>d</sup> At Day 1, patients received 600 mg of dupilumab.</p><p><sup>e</sup> At Day 1, patients received 200 mg (baseline weight &lt;30 kg) or 400 mg (baseline weight &ge;30 kg) of dupilumab.</p><p>&nbsp;</p><p>A greater proportion of patients randomised to dupilumab + TCS achieved an improvement in the peak pruritus NRS compared to placebo + TCS (defined as &ge;4-point improvement at week 4). See Figure 2.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image7.jpeg" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;left:0;text-align:left;margin-left:72.6pt;
  margin-top:34.05pt;width:236.65pt;height:191.6pt;z-index:13;visibility:visible;
  mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
  mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/sa000712/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="316" height="255" src="file:///C:/Users/sa000712/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Figure 2: Proportion of Paediatric Subjects with &ge;4-point Improvement on the Peak Pruritus NRS in AD-1652<sup>a</sup> (FAS)<sup>b</sup></p><p><sup>a</sup> In the primary analyses of the efficacy endpoints, patients who received rescue treatment or with missing data were considered non-responders.</p><p><sup>b</sup> Full Analysis Set (FAS) includes all patients randomised.</p><p>&nbsp;</p><p>The dupilumab groups significantly improved patient-reported symptoms, the impact of AD on sleep and health-related quality of life as measured by POEM, SCORAD, and CDLQI scores at 16 weeks compared to placebo.</p><p>&nbsp;</p><p>The long-term efficacy of dupilumab + TCS in paediatric patients with atopic dermatitis who had participated in the previous clinical trials of dupilumab + TCS was assessed in an open-label extension study (AD-1434). Efficacy data from this trial suggests that clinical benefit provided at week 16 was sustained through week 52.</p><p>&nbsp;</p><p>Adults with atopic dermatitis</p><p>&nbsp;</p><p>For clinical data in adults with atopic dermatitis please refer to the dupilumab 300 mg Summary of Product Characteristics.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in asthma</u></p><p>&nbsp;</p><p>The asthma development program included three randomised, double-blind, placebo-controlled, parallel-group, multi-centre studies (DRI12544, QUEST, and VENTURE) of 24 to 52 weeks in treatment duration which enrolled a total of 2,888 patients (12 years of age and older). Patients were enrolled without requiring a minimum baseline blood eosinophil or other type 2 inflammatory biomarkers (e.g. FeNO or IgE) level. Asthma treatment guidelines define type 2 inflammation as eosinophilia &ge; 150 cells/mcL and/or FeNO &ge; 20 ppb. In DRI12544 and QUEST, the pre-specified subgroup analyses included blood eosinophils &ge; 150 and &ge; 300 cells/mcL, FeNO &ge; 25 and &ge; 50 ppb.</p><p>&nbsp;</p><p>DRI12544 was a 24-week dose-ranging study which included 776 patients (18 years of age and older). Dupilumab compared with placebo was evaluated in adult patients with moderate to severe asthma on a medium-to-high dose inhaled corticosteroid and a long acting beta agonist. The primary endpoint was change from baseline to week 12 in FEV1 (L). Annualized rate of severe asthma exacerbation events during the 24-week placebo controlled treatment period was also determined. Results were evaluated in the overall population (unrestricted by minimum baseline eosinophils or other type 2 inflammatory biomarkers) and subgroups based on baseline blood eosinophil count.</p><p>&nbsp;</p><p>QUEST was a 52-week confirmatory study which included 1,902 patients (12 years of age and older). Dupilumab compared with placebo was evaluated in 107 adolescent and 1,795 adult patients with persistent asthma on a medium-to-high dose inhaled corticosteroid (ICS) and a second controller medication. Patients requiring a third controller were allowed to participate in this trial. Patients were</p><p>randomised to receive either 200 mg (N=631) or 300 mg (N=633) Dupixent every other week (or matching placebo for either 200 mg (N = 317) or 300 mg (N= 321) every other week) following an initial dose of 400 mg, 600 mg or placebo respectively. The primary endpoints were the annualized rate of severe exacerbation events during the 52-week placebo controlled period and change from baseline in pre-bronchodilator FEV1 at week 12 in the overall population (unrestricted by minimum baseline eosinophils or other type 2 inflammatory biomarkers) and subgroups based on baseline blood eosinophils count and FeNO.</p><p>&nbsp;</p><p>VENTURE was a 24-week oral corticosteroid-reduction study in 210 patients with asthma unrestricted by baseline type 2 biomarker levels who required daily oral corticosteroids in addition to regular use of high dose inhaled corticosteroids plus an additional controller. After optimizing the OCS dose during the screening period, patients received 300 mg dupilumab (n=103) or placebo (n=107) once every other week for 24 weeks following an initial dose of 600 mg or placebo. Patients continued to receive their existing asthma medicine during the study; however their OCS dose was reduced every 4 weeks during the OCS reduction phase (week 4-20), as long as asthma control was maintained. The primary endpoint was the percent reduction in oral corticosteroid dose assessed in the overall population, based on a comparison of the oral corticosteroid dose at weeks 20 to 24 that maintained asthma control with the previously optimized (at baseline) oral corticosteroid dose.</p><p>&nbsp;</p><p>The demographics and baseline characteristics of these 3 studies are provided in Table 6 below.</p><p>&nbsp;</p><p>Table 6: Demographics and Baseline Characteristics of Asthma Trials</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>DRI12544 (n = 776)</strong></p></td><td style="vertical-align:top"><p><strong>QUEST (n = 1902)</strong></p></td><td style="vertical-align:top"><p><strong>VENTURE (n=210)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean age (years) (SD)</p></td><td style="vertical-align:top"><p>48.6 (13.0)</p></td><td style="vertical-align:top"><p>47.9 (15.3)</p></td><td style="vertical-align:top"><p>51.3 (12.6)</p></td></tr><tr><td style="vertical-align:top"><p>% Female</p></td><td style="vertical-align:top"><p>63.1</p></td><td style="vertical-align:top"><p>62.9</p></td><td style="vertical-align:top"><p>60.5</p></td></tr><tr><td style="vertical-align:top"><p>% White</p></td><td style="vertical-align:top"><p>78.2</p></td><td style="vertical-align:top"><p>82.9</p></td><td style="vertical-align:top"><p>93.8</p></td></tr><tr><td style="vertical-align:top"><p>Duration of Asthma (years), mean &plusmn; SD</p></td><td style="vertical-align:top"><p>22.03 (15.42)</p></td><td style="vertical-align:top"><p>20.94 (15.36)</p></td><td style="vertical-align:top"><p>19.95 (13.90)</p></td></tr><tr><td style="vertical-align:top"><p>Never smoked, (%)</p></td><td style="vertical-align:top"><p>77.4</p></td><td style="vertical-align:top"><p>80.7</p></td><td style="vertical-align:top"><p>80.5</p></td></tr><tr><td style="vertical-align:top"><p>Mean exacerbations in previous year <em>&plusmn; </em>SD</p></td><td style="vertical-align:top"><p>2.17 (2.14)</p></td><td style="vertical-align:top"><p>2.09 (2.15)</p></td><td style="vertical-align:top"><p>2.09 (2.16)</p></td></tr><tr><td style="vertical-align:top"><p>High dose ICS use (%)<sup>a</sup></p></td><td style="vertical-align:top"><p>49.5</p></td><td style="vertical-align:top"><p>51.5</p></td><td style="vertical-align:top"><p>88.6</p></td></tr><tr><td style="vertical-align:top"><p>Pre-dose FEV1 (L) at baseline <em>&plusmn; </em>SD</p></td><td style="vertical-align:top"><p>1.84 (0.54)</p></td><td style="vertical-align:top"><p>1.78 (0.60)</p></td><td style="vertical-align:top"><p>1.58 (0.57)</p></td></tr><tr><td style="vertical-align:top"><p>Mean percent predicted FEV1 at baseline (%)(<em>&plusmn; </em>SD)</p></td><td style="vertical-align:top"><p>60.77 (10.72)</p></td><td style="vertical-align:top"><p>58.43 (13.52)</p></td><td style="vertical-align:top"><p>52.18 (15.18)</p></td></tr><tr><td style="vertical-align:top"><p>% Reversibility (&plusmn; SD)</p></td><td style="vertical-align:top"><p>26.85 (15.43)</p></td><td style="vertical-align:top"><p>26.29 (21.73)</p></td><td style="vertical-align:top"><p>19.47 (23.25)</p></td></tr><tr><td style="vertical-align:top"><p>Mean ACQ-5 score (&plusmn; SD)</p></td><td style="vertical-align:top"><p>2.74 (0.81)</p></td><td style="vertical-align:top"><p>2.76 (0.77)</p></td><td style="vertical-align:top"><p>2.50 (1.16)</p></td></tr><tr><td style="vertical-align:top"><p>Mean AQLQ score (&plusmn; SD)</p></td><td style="vertical-align:top"><p>4.02 (1.09)</p></td><td style="vertical-align:top"><p>4.29 (1.05)</p></td><td style="vertical-align:top"><p>4.35 (1.17)</p></td></tr><tr><td style="vertical-align:top"><p>Atopic Medical History % Overall (AD %, NP %, AR %)</p></td><td style="vertical-align:top"><p>72.9</p><p>(8.0, 10.6, 61.7)</p></td><td style="vertical-align:top"><p>77.7</p><p>(10.3, 12.7, 68.6)</p></td><td style="vertical-align:top"><p>72.4</p><p>(7.6, 21.0, 55.7)</p></td></tr><tr><td style="vertical-align:top"><p>Mean FeNO ppb (&plusmn; SD)</p></td><td style="vertical-align:top"><p>39.10 (35.09)</p></td><td style="vertical-align:top"><p>34.97 (32.85)</p></td><td style="vertical-align:top"><p>37.61 (31.38)</p></td></tr><tr><td style="vertical-align:top"><p>% patients with FeNO ppb</p><p>&ge; 25</p><p>&ge; 50</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>49.9</p><p>21.6</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>49.6</p><p>20.5</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>54.3</p><p>25.2</p></td></tr><tr><td style="vertical-align:top"><p>Mean total IgE IU/mL <strong>(&plusmn; </strong>SD)</p></td><td style="vertical-align:top"><p>435.05 (753.88)</p></td><td style="vertical-align:top"><p>432.40 (746.66)</p></td><td style="vertical-align:top"><p>430.58 (775.96)</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline Eosinophil count (&plusmn; SD) cells/mcL</p></td><td style="vertical-align:top"><p>350 (430)</p></td><td style="vertical-align:top"><p>360 (370)</p></td><td style="vertical-align:top"><p>350 (310)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:667px"><tbody><tr><td style="vertical-align:top; width:309px"><p>% patients with EOS</p><p>&ge; 150 cells/mcL</p><p>&ge; 300 cells/mcL</p></td><td style="vertical-align:top; width:123px"><p><strong>&nbsp;</strong></p><p>77.8</p><p>41.9</p></td><td style="vertical-align:top; width:115px"><p><strong>&nbsp;</strong></p><p>71.4</p><p>43.7</p></td><td style="vertical-align:top; width:119px"><p><strong>&nbsp;</strong></p><p>71.4</p><p>42.4</p></td></tr></tbody></table><p><br /><span style="text-align:unset">ICS = inhaled corticosteroid; FEV1 = Forced expiratory volume in 1 second; ACQ-5 = Asthma Control Questionnaire-5; AQLQ = Asthma Quality of Life Questionnaire; AD = atopic dermatitis; NP = nasal polyposis;</span></p><p>AR = allergic rhinitis; FeNO = fraction of exhaled nitric oxide; EOS = blood eosinophil</p><p><sup>a</sup>The population in dupilumab asthma trials included patients on medium and high dose ICS. The medium ICS dose was defined as equal to 500 mcg fluticasone or equivalent per day.</p><p>&nbsp;</p><p><em><u>Exacerbations</u></em></p><p><em>&nbsp;</em></p><p>In the overall population in DRI12544 and QUEST subjects receiving either dupilumab 200 mg or 300 mg every other week had significant reductions in the rate of severe asthma exacerbations compared to placebo. There were greater reductions in exacerbations in subjects with higher baseline levels of type 2 inflammatory biomarkers such as blood eosinophils or FeNO (Table 7 and Table 8).</p><p>&nbsp;</p><p><strong>Table 7: Rate of Severe Exacerbations in DRI12544 and QUEST (Baseline Blood Eosinophil Levels &ge; 150 and &ge; 300 cells/mcL)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Treatment</strong></p></td><td colspan="10" style="vertical-align:top"><p><strong>Baseline Blood EOS</strong></p></td></tr><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p><strong>&ge;150 cells/mcL</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>&ge;300 cells/mcL</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Exacerbations per Year</strong></p></td><td colspan="3" rowspan="2" style="vertical-align:top"><p><strong>%</strong></p><p><strong>Reduction</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Exacerbations per Year</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>%</strong></p><p><strong>Reduction</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Rate (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Rate Ratio (95%CI)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Rate (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Rate Ratio (95%CI)</strong></p></td></tr><tr><td colspan="12" style="vertical-align:top"><p><strong><em>All Severe Exacerbations</em></strong></p></td></tr><tr><td colspan="12" style="vertical-align:top"><p><strong>DRI12544 study</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 200 mg Q2W</p></td><td colspan="2" style="vertical-align:top"><p>120</p></td><td style="vertical-align:top"><p>0.29</p><p>(0.16, 0.53)</p></td><td colspan="2" style="vertical-align:top"><p>0.28<sup>a</sup> (0.14, 0.55)</p></td><td style="vertical-align:top"><p>72%</p></td><td colspan="2" style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>0.30</p><p>(0.13, 0.68)</p></td><td style="vertical-align:top"><p>0.29<sup>c</sup> (0.11, 0.76)</p></td><td style="vertical-align:top"><p>71%</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 300 mg Q2W</p></td><td colspan="2" style="vertical-align:top"><p>129</p></td><td style="vertical-align:top"><p>0.28</p><p>(0.16, 0.50)</p></td><td colspan="2" style="vertical-align:top"><p>0.27<sup>b</sup> (0.14, 0.52)</p></td><td style="vertical-align:top"><p>73%</p></td><td colspan="2" style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>0.20</p><p>(0.08, 0.52)</p></td><td style="vertical-align:top"><p>0.19<sup>d</sup> (0.07, 0.56)</p></td><td style="vertical-align:top"><p>81%</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td colspan="2" style="vertical-align:top"><p>127</p></td><td style="vertical-align:top"><p>1.05</p><p>(0.69, 1.60)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>1.04</p><p>(0.57, 1.90)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="12" style="vertical-align:top"><p><strong>QUEST study</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 200 mg</p><p>Q2W</p></td><td colspan="2" style="vertical-align:top"><p>437</p></td><td style="vertical-align:top"><p>0.45</p><p>(0.37, 0.54)</p></td><td colspan="2" style="vertical-align:top"><p>0.44<sup>e</sup> (0.34,0.58)</p></td><td style="vertical-align:top"><p>56%</p></td><td colspan="2" style="vertical-align:top"><p>264</p></td><td style="vertical-align:top"><p>0.37</p><p>(0.29, 0.48)</p></td><td style="vertical-align:top"><p>0.34<sup>e</sup> (0.24,0.48)</p></td><td style="vertical-align:top"><p>66%</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td colspan="2" style="vertical-align:top"><p>232</p></td><td style="vertical-align:top"><p>1.01</p><p>(0.81, 1.25)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>148</p></td><td style="vertical-align:top"><p>1.08</p><p>(0.85, 1.38)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 300 mg Q2W</p></td><td colspan="2" style="vertical-align:top"><p>452</p></td><td style="vertical-align:top"><p>0.43</p><p>(0.36, 0.53)</p></td><td colspan="2" style="vertical-align:top"><p>0.40 e</p><p>(0.31,0.53)</p></td><td style="vertical-align:top"><p>60%</p></td><td colspan="2" style="vertical-align:top"><p>277</p></td><td style="vertical-align:top"><p>0.40</p><p>(0.32, 0.51)</p></td><td style="vertical-align:top"><p>0.33<sup>e</sup> (0.23,0.45)</p></td><td style="vertical-align:top"><p>67%</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td colspan="2" style="vertical-align:top"><p>237</p></td><td style="vertical-align:top"><p>1.08</p><p>(0.88, 1.33)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>142</p></td><td style="vertical-align:top"><p>1.24</p><p>(0.97, 1.57)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><sup>a</sup>p-value = 0.0003, <sup>b</sup>p-value = 0.0001, <sup>c</sup>p-value = 0.0116, <sup>d</sup>p-value = 0.0024, <sup>e</sup>p-value &lt;0.0001</p><p>Table 8: Rate of Severe Exacerbations in QUEST Defined by Baseline FeNO Subgroups</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Exacerbations per Year</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Percent Reduction</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Rate (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Rate Ratio (95%CI)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>FeNO &ge; 25 ppb</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 200 mg Q2W</p></td><td style="vertical-align:top"><p>299</p></td><td style="vertical-align:top"><p>0.35 (0.27, 0.45)</p></td><td style="vertical-align:top"><p>0.35 (0.25, 0.50)<sup>a</sup></p></td><td style="vertical-align:top"><p>65%</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>162</p></td><td style="vertical-align:top"><p>1.00 (0.78, 1.30)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 300 mg Q2W</p></td><td style="vertical-align:top"><p>310</p></td><td style="vertical-align:top"><p>0.43 (0.35, 0.54)</p></td><td style="vertical-align:top"><p>0.39 (0.28, 0.54) <sup>a</sup></p></td><td style="vertical-align:top"><p>61%</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>172</p></td><td style="vertical-align:top"><p>1.12 (0.88, 1.43)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>FeNO &ge; 50 ppb</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 200 mg Q2W</p></td><td style="vertical-align:top"><p>119</p></td><td style="vertical-align:top"><p>0.33 (0.22, 0.48)</p></td><td style="vertical-align:top"><p>0.31 (0.18, 0.52) <sup>a</sup></p></td><td style="vertical-align:top"><p>69%</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>1.057 (0.72, 1.55)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 300 mg Q2W</p></td><td style="vertical-align:top"><p>124</p></td><td style="vertical-align:top"><p>0.39 (0.27, 0.558)</p></td><td style="vertical-align:top"><p>0.31 (0.19, 0.49) <sup>a</sup></p></td><td style="vertical-align:top"><p>69%</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>1.27 (0.90, 1.80)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>p-value &lt;0.0001</p><p>&nbsp;</p><p>In the pooled analysis of DRI12544 and QUEST, hospitalizations and/or emergency room visits due to severe exacerbations were reduced by 25.5% and 46.9% with dupilumab 200 mg or 300 mg every other week, respectively.</p><p>&nbsp;</p><p><em><u>Lung Function</u></em></p><p><em>&nbsp;</em></p><p>Clinically significant increases in pre-bronchodilator FEV1 were observed at week 12 for DRI12544 and QUEST. There were greater improvements in FEV1 in the subjects with higher baseline levels of type 2 inflammatory biomarkers such as blood eosinophils or FeNO (Table 9 and Table 10).</p><p>&nbsp;</p><p>Significant improvements in FEV1 were observed as early as week 2 following the first dose of dupilumab for both the 200 mg and 300 mg dose strengths and were maintained through week 24 (DRI12544) and week 52 in QUEST (see Figure 3).</p><p>&nbsp;</p><p>Figure 3: Mean Change from Baseline in Pre-Bronchodilator FEV1 (L) Over Time (Baseline Eosinophils &ge; 150 and &ge; 300 cells/mcL and FeNO &ge;25 ppb) in QUEST</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>QUEST: Blood Eosinophils</strong></p><p><strong>&ge; 150 cells/mcL</strong></p><p>&nbsp;</p><p><strong>QUEST: Blood Eosinophils</strong></p><p><strong>&ge; 300 cells/mcL</strong></p><p>&nbsp;</p><p><strong>QUEST: FeNO &ge; 25 ppb</strong></p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1026"
 style='width:431.45pt;height:112.8pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="8629,2256">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
  top:32;width:5717;height:2224'>
  <v:imagedata src="file:///C:/Users/sa000712/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="_x0000_s1028" type="#_x0000_t75" style='position:absolute;
  left:5775;width:2854;height:2230'>
  <v:imagedata src="file:///C:/Users/sa000712/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg"
   o:title=""/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="576" height="150" src="file:///C:/Users/sa000712/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:431.45pt;height:112.8pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>Table 9: Mean Change from Baseline in Pre-Bronchodilator FEV1 at Week 12 in DRI12544 and QUEST (Baseline Blood Eosinophil Levels &ge; 150 and &ge; 300 cells/mcL)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>Baseline Blood EOS</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>&ge; 150 cells/mcL</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>&ge; 300 cells/mcL</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>LS Mean &Delta; From baseline</strong></p><p><strong>L (%)</strong></p></td><td style="vertical-align:top"><p><strong>LS Mean Difference vs. placebo</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>LS mean &Delta; From baseline</strong></p><p><strong>L (%)</strong></p></td><td style="vertical-align:top"><p><strong>LS Mean Difference vs. placebo</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>DRI12544 study</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 200 mg</p><p>Q2W</p></td><td style="vertical-align:top"><p>120</p></td><td style="vertical-align:top"><p>0.32 (18.25)</p></td><td style="vertical-align:top"><p>0.23<sup>a</sup></p><p>(0.13, 0.33)</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>0.43 (25.9)</p></td><td style="vertical-align:top"><p>0.26<sup>c</sup> (0.11, 0.40)</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 300 mg Q2W</p></td><td style="vertical-align:top"><p>129</p></td><td style="vertical-align:top"><p>0.26 (17.1)</p></td><td style="vertical-align:top"><p>0.18<sup>b</sup></p><p>(0.08, 0.27)</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>0.39 (25.8)</p></td><td style="vertical-align:top"><p>0.21<sup>d</sup> (0.06, 0.36)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>127</p></td><td style="vertical-align:top"><p>0.09 (4.36)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>0.18 (10.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>QUEST study</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 200 mg Q2W</p></td><td style="vertical-align:top"><p>437</p></td><td style="vertical-align:top"><p>0.36 (23.6)</p></td><td style="vertical-align:top"><p>0.17<sup>e</sup> (0.11, 0.23)</p></td><td style="vertical-align:top"><p>264</p></td><td style="vertical-align:top"><p>0.43 (29.0)</p></td><td style="vertical-align:top"><p>0.21<sup>e</sup> (0.13, 0.29)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>232</p></td><td style="vertical-align:top"><p>0.18 (12.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>148</p></td><td style="vertical-align:top"><p>0.21 (15.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab</p><p>300 mg Q2W</p></td><td style="vertical-align:top"><p>452</p></td><td style="vertical-align:top"><p>0.37 (25.3)</p></td><td style="vertical-align:top"><p>0.15<sup>e</sup></p><p>(0.09, 0.21)</p></td><td style="vertical-align:top"><p>277</p></td><td style="vertical-align:top"><p>0.47 (32.5)</p></td><td style="vertical-align:top"><p>0.24<sup>e</sup> (0.16, 0.32)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>237</p></td><td style="vertical-align:top"><p>0.22 (14.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>142</p></td><td style="vertical-align:top"><p>0.22 (14.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>p-value &lt;0.0001, <sup>b</sup>p-value = 0.0004, <sup>c</sup>p-value = 0.0008, <sup>d</sup>p-value = 0.0063, <sup>e</sup>p-value &lt;0.0001</p><p>&nbsp;</p><p><strong>Table 10: Mean Change from Baseline in Pre-Bronchodilator FEV1 at Week 12 and Week 52 in QUEST by Baseline FeNO Subgroups</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Treatment</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>At Week 12</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>At Week 52</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>LS Mean &Delta;</strong></p><p><strong>From baseline L (%)</strong></p></td><td style="vertical-align:top"><p><strong>LS Mean Difference</strong></p><p><strong>vs. placebo (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>LS Mean &Delta;</strong></p><p><strong>From baseline L (%)</strong></p></td><td style="vertical-align:top"><p><strong>LS Mean Difference</strong></p><p><strong>vs. placebo (95% CI)</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>FeNO &ge; 25 ppb</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 200 mg Q2W</p></td><td style="vertical-align:top"><p>288</p></td><td style="vertical-align:top"><p>0.44 (29.0%)</p></td><td style="vertical-align:top"><p>0.23 (0.15, 0.31)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.49 (31.6%)</p></td><td style="vertical-align:top"><p>0.30 (0.22, 0.39)<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>157</p></td><td style="vertical-align:top"><p>0.21 (14.1%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.18 (13.2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab</p><p>300 mg Q2W</p></td><td style="vertical-align:top"><p>295</p></td><td style="vertical-align:top"><p>0.45 (29.8%)</p></td><td style="vertical-align:top"><p>0.24 (0.16, 0.31)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.45 (30.5%)</p></td><td style="vertical-align:top"><p>0.23 (0.15, 0.31)<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>167</p></td><td style="vertical-align:top"><p>0.21 (13.7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.22 (13.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>FeNO &ge; 50 ppb</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 200 mg Q2W</p></td><td style="vertical-align:top"><p>114</p></td><td style="vertical-align:top"><p>0.53 (33.5%)</p></td><td style="vertical-align:top"><p>0.30 (0.17, 0.44)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.59 (36.4%)</p></td><td style="vertical-align:top"><p>0.38 (0.24, 0.53)<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>69</p></td><td style="vertical-align:top"><p>0.23 (14.9%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.21 (14.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 300 mg Q2W</p></td><td style="vertical-align:top"><p>113</p></td><td style="vertical-align:top"><p>0.59 (37.6%)</p></td><td style="vertical-align:top"><p>0.39 (0.26, 0.52)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.55 (35.8%)</p></td><td style="vertical-align:top"><p>0.30 (0.16, 0.44)<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>73</p></td><td style="vertical-align:top"><p>0.19 (13.0%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.25 (13.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>p-value &lt; 0.0001</p><p><em>Quality of Life/Patient-Reported Outcomes in Asthma</em></p><p><em>&nbsp;</em></p><p>Pre-specified secondary endpoint of ACQ-5 and AQLQ(S) responder rates were analysed at 24 weeks (DRI12544 and VENTURE) and at 52 weeks (QUEST). The responder rate was defined as an improvement in score of 0.5 or more (scale range 0-6 for ACQ-5 and 1-7 for AQLQ(S)).</p><p>Improvements in ACQ-5 and AQLQ(S) were observed as early as week 2 and maintained for 24 weeks in DRI12544 study and 52 weeks in QUEST study. Similar results were observed in VENTURE. The ACQ-5 and AQLQ(S) responder rate results in patients with elevated baseline biomarkers of type 2 inflammation in QUEST at week 52 are presented in Table 11.</p><p>&nbsp;</p><p>Table 11: ACQ-5 and AQLQ(S) Responder Rates at Week 52 in QUEST</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>PRO</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Treatment</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>EOS</strong></p><p><strong>&ge;150 cells/mcL</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>EOS</strong></p><p>&ge;<strong>300 cells/mcL</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>FeNO</strong></p><p><strong>&ge;25 ppb</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Responder</strong><strong> </strong><strong>rate %</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Responder</strong><strong> </strong><strong>rate (%)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Responder</strong><strong> </strong><strong>rate (%)</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>ACQ-5</strong></p></td><td style="vertical-align:top"><p>Dupilumab 200 mg Q2W</p></td><td style="vertical-align:top"><p>39</p><p>5</p></td><td style="vertical-align:top"><p>72.9</p></td><td style="vertical-align:top"><p>239</p></td><td style="vertical-align:top"><p>74.5</p></td><td style="vertical-align:top"><p>262</p></td><td style="vertical-align:top"><p>74.4</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>20</p><p>1</p></td><td style="vertical-align:top"><p>64.2</p></td><td style="vertical-align:top"><p>124</p></td><td style="vertical-align:top"><p>66.9</p></td><td style="vertical-align:top"><p>141</p></td><td style="vertical-align:top"><p>65.2</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 300 mg Q2W</p></td><td style="vertical-align:top"><p>40</p><p>8</p></td><td style="vertical-align:top"><p>70.1</p></td><td style="vertical-align:top"><p>248</p></td><td style="vertical-align:top"><p>71.0</p></td><td style="vertical-align:top"><p>277</p></td><td style="vertical-align:top"><p>75.8</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>21</p><p>7</p></td><td style="vertical-align:top"><p>64.5</p></td><td style="vertical-align:top"><p>129</p></td><td style="vertical-align:top"><p>64.3</p></td><td style="vertical-align:top"><p>159</p></td><td style="vertical-align:top"><p>64.2</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>AQLQ(S)</strong></p></td><td style="vertical-align:top"><p>Dupilumab 200 mg Q2W</p></td><td style="vertical-align:top"><p>39</p><p>5</p></td><td style="vertical-align:top"><p>66.6</p></td><td style="vertical-align:top"><p>239</p></td><td style="vertical-align:top"><p>71.1</p></td><td style="vertical-align:top"><p>262</p></td><td style="vertical-align:top"><p>67.6</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>20</p><p>1</p></td><td style="vertical-align:top"><p>53.2</p></td><td style="vertical-align:top"><p>124</p></td><td style="vertical-align:top"><p>54.8</p></td><td style="vertical-align:top"><p>141</p></td><td style="vertical-align:top"><p>54.6</p></td></tr><tr><td style="vertical-align:top"><p>Dupilumab 300 mg Q2W</p></td><td style="vertical-align:top"><p>40</p><p>8</p></td><td style="vertical-align:top"><p>62.0</p></td><td style="vertical-align:top"><p>248</p></td><td style="vertical-align:top"><p>64.5</p></td><td style="vertical-align:top"><p>277</p></td><td style="vertical-align:top"><p>65.3</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>21</p><p>7</p></td><td style="vertical-align:top"><p>53.9</p></td><td style="vertical-align:top"><p>129</p></td><td style="vertical-align:top"><p>55.0</p></td><td style="vertical-align:top"><p>159</p></td><td style="vertical-align:top"><p>58.5</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Oral Corticosteroid Reduction Study (VENTURE)</u></p><p>&nbsp;</p><p>VENTURE evaluated the effect of dupilumab on reducing the use of maintenance oral corticosteroids. Baseline characteristics are presented in Table 6. All patients were on oral corticosteroids for at least 6 months prior to the study initiation. The baseline mean oral corticosteroid use was 11.75 mg in the placebo group and 10.75 mg in the group receiving dupilumab.</p><p>&nbsp;</p><p>In this 24-week trial, asthma exacerbations (defined as a temporary increase in oral corticosteroid dose for at least 3 days) were reduced by 59% in subjects receiving dupilumab compared with those receiving placebo (annualized rate 0.65 and 1.60 for the dupilumab and placebo group, respectively; rate ratio 0.41 [95% CI 0.26, 0.63]) and improvement in pre-bronchodilator FEV1 from baseline to week 24 was greater in subjects receiving dupilumab compared with those receiving placebo (LS mean difference for dupilumab versus placebo of 0.22 L [95% CI: 0.09 to 0.34 L]). Effects on lung function, on oral steroid and exacerbation reduction were similar irrespective of baseline levels of type 2 inflammatory biomarkers (e.g. blood eosinophils, FeNO). The ACQ-5 and AQLQ(S) were also assessed in VENTURE and showed improvements similar to those in QUEST.</p><p>&nbsp;</p><p>The results for VENTURE by baseline biomarkers are presented in the Table 12.</p><p><strong>Table 12: Effect of dupilumab on OCS dose reduction, VENTURE (Baseline Blood Eosinophil Levels &ge; 150 and &ge; 300 cells/mcL and FeNO &ge; 25 ppb)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Baseline Blood EOS</strong></p><p><strong>&ge; 150 cells/mcL</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Baseline Blood EOS</strong></p><p><strong>&ge; 300 cells/mcL</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>FeNO &ge; 25 ppb</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dupilumab 300 mg Q2W</strong></p><p><strong>N=81</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo</strong><strong> </strong><strong>N=69</strong></p></td><td style="vertical-align:top"><p><strong>Dupilumab 300 mg Q2W</strong></p><p><strong>N=48</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><strong> </strong><strong>N=41</strong></p></td><td style="vertical-align:top"><p><strong>Dupilumab 300 mg Q2W</strong></p><p><strong>N=57</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><strong> </strong><strong>N=57</strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>Primary endpoint (week 24)</strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>Percent reduction in OCS from baseline</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean overall percent reduction</p></td><td style="vertical-align:top"><p>75.91</p></td><td colspan="2" style="vertical-align:top"><p>46.51</p></td><td style="vertical-align:top"><p>79.54</p></td><td style="vertical-align:top"><p>42.71</p></td><td style="vertical-align:top"><p>77.46</p></td><td style="vertical-align:top"><p>42.93</p></td></tr><tr><td style="vertical-align:top"><p>from baseline (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Difference (% [95% CI])</p></td><td style="vertical-align:top"><p>29.39<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>36.83<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>34.53<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>(Dupilumab vs. placebo)</p></td><td style="vertical-align:top"><p>(15.67, 43.12)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(18.94, 54.71)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(19.08, 49.97)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median % reduction in daily OCS dose from baseline</p></td><td style="vertical-align:top"><p>100</p></td><td colspan="2" style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>Percent reduction from baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>100%</p></td><td style="vertical-align:top"><p>54.3</p></td><td colspan="2" style="vertical-align:top"><p>33.3</p></td><td style="vertical-align:top"><p>60.4</p></td><td style="vertical-align:top"><p>31.7</p></td><td style="vertical-align:top"><p>52.6</p></td><td style="vertical-align:top"><p>28.1</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 90%</p></td><td style="vertical-align:top"><p>58.0</p></td><td colspan="2" style="vertical-align:top"><p>34.8</p></td><td style="vertical-align:top"><p>66.7</p></td><td style="vertical-align:top"><p>34.1</p></td><td style="vertical-align:top"><p>54.4</p></td><td style="vertical-align:top"><p>29.8</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 75%</p></td><td style="vertical-align:top"><p>72.8</p></td><td colspan="2" style="vertical-align:top"><p>44.9</p></td><td style="vertical-align:top"><p>77.1</p></td><td style="vertical-align:top"><p>41.5</p></td><td style="vertical-align:top"><p>73.7</p></td><td style="vertical-align:top"><p>36.8</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 50%</p></td><td style="vertical-align:top"><p>82.7</p></td><td colspan="2" style="vertical-align:top"><p>55.1</p></td><td style="vertical-align:top"><p>85.4</p></td><td style="vertical-align:top"><p>53.7</p></td><td style="vertical-align:top"><p>86.0</p></td><td style="vertical-align:top"><p>50.9</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 0%</p></td><td style="vertical-align:top"><p>87.7</p></td><td colspan="2" style="vertical-align:top"><p>66.7</p></td><td style="vertical-align:top"><p>85.4</p></td><td style="vertical-align:top"><p>63.4</p></td><td style="vertical-align:top"><p>89.5</p></td><td style="vertical-align:top"><p>66.7</p></td></tr><tr><td style="vertical-align:top"><p>No reduction or any increase in</p></td><td style="vertical-align:top"><p>12.3</p></td><td colspan="2" style="vertical-align:top"><p>33.3</p></td><td style="vertical-align:top"><p>14.6</p></td><td style="vertical-align:top"><p>36.6</p></td><td style="vertical-align:top"><p>10.5</p></td><td style="vertical-align:top"><p>33.3</p></td></tr><tr><td style="vertical-align:top"><p>OCS dose, or dropped out of</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>study</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>Secondary endpoint (week 24)<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients</p><p>achieving a reduction of OCS dose to &lt;5 mg/day</p></td><td colspan="2" style="vertical-align:top"><p>77</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>34</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>4.29<sup>c</sup> (2.04, 9.04)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>8.04<sup>d</sup> (2.71, 23.82)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7.21<sup>b</sup> (2.69, 19.28)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><sup>a</sup>Model estimates by logistic regression</p><p><sup>b</sup>p-value &lt;0.0001</p><p><sup>c</sup>p-value =0.0001</p><p><sup>d</sup>p-value =0.0002</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Atopic dermatitis</p><p>The safety and efficacy of dupilumab have been established in 12 to 17 years old with moderate-to- severe atopic dermatitis in study AD-1526 which included 251 adolescents. The safety and efficacy of dupilumab have been established in 6 to 11 years old with severe atopic dermatitis in study AD-1652 which included 367 paediatric patients. Use is supported by study AD-1434 which enrolled patients who had completed AD-1526 (136 moderate and 64 severe at the time of enrolment in study AD- 1434) and patients who had completed study AD-1652 (110 moderate and 72 severe at the time of enrolment in in study AD-1434). The safety and efficacy were generally consistent between paediatric, adolescent, and adult patients (see section 4.8)<em>. </em>Safety and efficacy in paediatric patients (&lt;6 years of age) with atopic dermatitis have not been established.</p><p>&nbsp;</p><p>Asthma</p><p>A total of 107 adolescents aged 12 to 17 years with moderate to severe asthma were enrolled in QUEST study and received either 200 mg (N=21) or 300 mg (N=18) dupilumab (or matching placebo either 200 mg [N=34] or 300 mg [N=34]) every other week. Efficacy with respect to severe asthma exacerbations and lung function was observed in both adolescents and adults. For both the 200 mg and 300 mg every other week doses, significant improvements in FEV1 (LS mean change from&nbsp;</p><p>baseline at eek 12) were observed (0.36 L and 0.27 L, respectively). For the 200 mg every other week dose, patients had a reduction in the rate of severe exacerbations that was consistent with adults. Safety and efficacy in paediatric patients (&lt; 12 years of age) with severe asthma have not been established.</p><p>The adverse event profile in adolescents was generally similar to the adults.</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with dupilumab in one or more subset of the paediatric population in atopic dermatitis and asthma (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of dupilumab is similar in patients with atopic dermatitis and asthma. <u>Absorption</u></p><p>After a single subcutaneous (SC) dose of 75-600 mg dupilumab, median times to maximum concentration in serum (tmax) were 3-7 days. The absolute bioavailability of dupilumab following a SC dose is similar between AD and asthma patients, ranging between 61% and 64 %, as determined by a population pharmacokinetics (PK) analysis.</p><p>&nbsp;</p><p>Steady-state concentrations were achieved by week 16 following the administration of 600 mg starting dose and 300 mg dose every other week. Across clinical trials, the mean &plusmn;SD steady-state trough concentrations ranged from 60.3&plusmn;35.1 mcg/mL to 79.9&plusmn;41.4 mcg/mL for 300 mg dose and from 29.2&plusmn;18.7 to 36.5&plusmn;22.2 mcg/mL for 200 mg dose administered every other week.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>A volume of distribution for dupilumab of approximately 4.6 L was estimated by population PK analysis, indicating that dupilumab is distributed primarily in the vascular system.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Specific metabolism studies were not conducted because dupilumab is a protein. Dupilumab is expected to degrade to small peptides and individual amino acids.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Dupilumab elimination is mediated by parallel linear and nonlinear pathways. At higher concentrations, dupilumab elimination is primarily through a non-saturable proteolytic pathway, while at lower concentrations, the non-linear saturable IL-4R &alpha; target-mediated elimination predominates.</p><p>After the last steady state dose, the median time for dupilumab concentrations to decrease below the lower limit of detection, estimated by population PK analysis, was 9 weeks for the 200 mg Q2W, 10- 11 weeks for the 300 mg Q2W regimen and 13 weeks for the 300 mg QW regimen.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>Due to nonlinear clearance, dupilumab exposure, as measured by area under the concentration-time curve, increases with dose in a greater than proportional manner following single SC doses from 75- 600 mg.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Gender</em></p><p>Gender was not found to be associated with any clinically meaningful impact on the systemic exposure of dupilumab determined by population PK analysis.</p><p><em>Elderly</em></p><p>Of the 1,472 patients with atopic dermatitis exposed to dupilumab in a phase 2 dose-ranging study or phase 3 placebo-controlled studies, a total of 67 were 65 years or older. Although no differences in safety or efficacy were observed between older and younger adult atopic dermatitis patients, the number of patients aged 65 and over is not sufficient to determine whether they respond differently from younger patients.</p><p>&nbsp;</p><p>Age was not found to be associated with any clinically meaningful impact on the systemic exposure of dupilumab determined by population PK analysis. However, there were only 61 patients over 65 years of age included in this analysis.</p><p>&nbsp;</p><p>Of the 1,977 patients with asthma exposed to dupilumab, a total of 240 patients were 65 years or older and 39 patients were 75 years or older. Efficacy and safety in this age group were similar to the overall study population.</p><p>&nbsp;</p><p><em>Race</em></p><p>Race was not found to be associated with any clinically meaningful impact on the systemic exposure of dupilumab by population PK analysis.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Dupilumab, as a monoclonal antibody, is not expected to undergo significant hepatic elimination. No clinical studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of dupilumab.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Dupilumab, as a monoclonal antibody, is not expected to undergo significant renal elimination. No clinical studies have been conducted to evaluate the effect of renal impairment on the pharmacokinetics of dupilumab. Population PK analysis did not identify mild or moderate renal impairment as having a clinically meaningful influence on the systemic exposure of dupilumab. Very limited data are available in patients with severe renal impairment.</p><p>&nbsp;</p><p><em>Body Weight</em></p><p>Dupilumab trough concentrations were lower in subjects with higher body weight with no meaningful impact on efficacy.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of dupilumab in paediatric patients (&lt; 6 years of age) with atopic dermatitis has not been studied.</p><p>&nbsp;</p><p>For adolescents 12 to 17 years of age with atopic dermatitis receiving every other week dosing (Q2W) with either 200 mg (&lt;60 kg) or 300 mg (&ge;60 kg), the mean &plusmn;SD steady state trough concentration of dupilumab was 54.5&plusmn;27.0 mcg/ml.</p><p>&nbsp;</p><p>For children 6 to 11 years of age with atopic dermatitis receiving every other week dosing (Q2W) with 200 mg (&ge;30 kg) or every four week dosing (Q4W) with 300 mg (&lt;30 kg), mean &plusmn; SD steady-state trough concentration was 86.0&plusmn;34.6 mcg/mL and 98.7&plusmn;33.2 mcg/mL, respectively.</p><p>&nbsp;</p><p>A total of 107 adolescents aged 12 to 17 years with asthma were enrolled in QUEST study. The mean</p><p>&plusmn;SD steady-state trough concentrations of dupilumab were 107&plusmn;51.6 mcg/mL and 46.7&plusmn;26.9 mcg/mL, respectively, for 300 mg or 200 mg administered every other week. No age-related pharmacokinetic difference was observed in adolescent patients after correction for body weight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity (including safety pharmacology endpoints) and toxicity to reproduction and development.</p><p>The mutagenic potential of dupilumab has not been evaluated; however monoclonal antibodies are not expected to alter DNA or chromosomes.</p><p>Carcinogenicity studies have not been conducted with dupilumab. An evaluation of the available evidence related to IL-4R&alpha; inhibition and animal toxicology data with surrogate antibodies does not suggest an increased carcinogenic potential for dupilumab.</p><p>During a reproductive toxicology study conducted in monkeys, using a surrogate antibody specific to the monkey IL-4R&alpha;, no fetal abnormalities were observed at dosages that saturate the IL-4R&alpha;.</p><p>An enhanced pre- and post-natal developmental study revealed no adverse effects in maternal animals or their offspring up to 6 months post-partum/post-birth.</p><p>Fertility studies conducted in male and female mice using a surrogate antibody against IL-4Ra showed no impairment of fertility (see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>arginine hydrochloride histidine</p><p>polysorbate 80 (E433) sodium acetate trihydrate glacial acetic acid (E260) sucrose</p><p>water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

If necessary, pre-filled syringes or pre-filled pens may be kept at room temperature up to 25°C for a maximum of 14 days. Do not store above 25°C. If the carton needs to be removed permanently from refrigerator, the date of removal may be recorded on the outer carton. After removal from the refrigerator, Dupixent must be used within 14 days or discarded.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>Store in the original carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dupixent 200 mg solution for injection in pre-filled syringe</u></p><p>1.14 ml solution in a siliconised type-1 clear glass pre-filled syringe with needle shield, with a fixed 27 gauge 12.7 mm (&frac12; inch), thin wall stainless steel staked needle.</p><p>&nbsp;</p><p>Pack size:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 pre-filled syringe</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 pre-filled syringes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Multipack containing 3 (3 packs of 1) pre-filled syringes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Multipack containing 6 (3 packs of 2) pre-filled syringes</p><p>&nbsp;</p><p><u>Dupixent 200 mg solution for injection in pre-filled pen</u></p><p>1.14 ml solution in a siliconised type-1 clear glass syringe in a pre-filled pen, with a fixed 27 gauge</p><p>12.7 mm (&frac12; inch), thin wall stainless steel staked needle.</p><p>&nbsp;</p><p>Pack size:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 pre-filled pen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 pre-filled pens</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 pre-filled pens</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6 pre-filled pens</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The instructions for the preparation and administration of Dupixent in a pre-filled syringe or in a pre- filled pen are given in the package leaflet.</p><p>&nbsp;</p><p>The solution should be clear to slightly opalescent, colourless to pale yellow. If the solution is cloudy, discoloured or contains visible particulate matter, the solution should not be used.</p><p>&nbsp;</p><p>After removing the 200 mg pre-filled syringe or pre-filled pen from the refrigerator, it should be allowed to reach room temperature up to 25&deg;C by waiting for 30 min before injecting Dupixent.</p><p>&nbsp;</p><p>The pre-filled syringe or the pre-filled pen should not be exposed to heat or direct sunlight and should not be shaken.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements. After use, place the pre-filled syringe or the pre-filled pen into a puncture-resistant container and discard as required by local regulations. Do not recycle the container. Keep the container out of sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                sanofi-aventis groupe 
54, rue La Boétie 75008 Paris
France


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jan 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>